WO2020033283A1 - Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc - Google Patents
Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc Download PDFInfo
- Publication number
- WO2020033283A1 WO2020033283A1 PCT/US2019/045041 US2019045041W WO2020033283A1 WO 2020033283 A1 WO2020033283 A1 WO 2020033283A1 US 2019045041 W US2019045041 W US 2019045041W WO 2020033283 A1 WO2020033283 A1 WO 2020033283A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- human
- antibody
- binding fragment
- antigen binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Definitions
- the present invention relates to combination therapies useful for the treatment of of a cell proliferation disorder, such as cancer.
- the invention relates to a combination therapy which comprises an antibody that binds to a Programmed Death 1 protein (PD-l) or an antigen binding fragment thereof, and the CCR5 antagonist vicriviroc.
- PD-l Programmed Death 1 protein
- sequence listing of the present application is submitted electronically via EFS-Web as an ASCII-formatted sequence listing, with a file name of“24628WOPCT- SEQLIST-31JUL2019”, a creation date of July 31, 2019 and a size of 21.1 KB.
- This sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.
- PD-l is recognized as an important player in immune regulation and the maintenance of peripheral tolerance. PD-l is moderately expressed on naive T, B and NKT cells and up-regulated by T/B cell receptor signaling on lymphocytes, monocytes and myeloid cells (Sharpe et al ., The function of programmed cell death 1 and its ligands in regulating
- PD-L1 Two known ligands for PD-l, PD-L1 (B7-H1) and PD-L2 (B7-DC), are expressed in human cancers arising in various tissues.
- PD-L1 expression correlated with poor prognosis and reduced overall survival irrespective of subsequent treatment (Dong et al., Nat Med. 8(8):793-800 (2002); Yang et al. Invest Ophthalmol Vis Sci. 49: 2518- 2525 (2008); Ghebeh et al. Neoplasia 8: 190-198 (2006); Hamanishi et al., Proc. Natl.
- PD-l expression on tumor infiltrating lymphocytes was found to mark dysfunctional T cells in breast cancer and melanoma (Ghebeh et al, BMC Cancer. 2008 8:5714- 15 (2008); Ahmadzadeh et al., Blood 114: 1537-1544 (2009)) and to correlate with poor prognosis in renal cancer (Thompson et al., Clinical Cancer Research 15: 1757-1761(2007)).
- PD-L1 expressing tumor cells interact with PD-l expressing T cells to attenuate T cell activation and evasion of immune surveillance, thereby contributing to an impaired immune response against the tumor.
- Immune therapies targeting the PD-l axis include monoclonal antibodies directed to the PD-l receptor (KEYTRUDATM (pembrolizumab), Merck and Co., Inc., Kenilworth, NJ, USA and OPDIVOTM (nivolumab), Bristol-Myers Squibb Company, Princeton, NJ, USA) and also those that bind to the PD-L1 ligand (MPDL3280A; TECENTRIQTM
- CRC colorectal cancer
- CRC is a heterogeneous disease with a number of etiological pathways, including the chromosomal instability (CIN) pathway, the microsatellite instability (MSI) pathway, and CpG island methylator phenotype (CIMP).
- CRC may be divided via molecular phenotyping into tumors with normal deoxyribonucleic (DNA) mismatch repair (MMR) function and those with DNA MMR deficient (MMR-D). Tumors showing the presence of MSI are classified as MSI-H (microsatellite instability-high), depending on the extent of instability in the markers tested; whereas tumors without this characteristic are classified as MSS.
- MSI-H microsatellite instability-high
- MSI CRC composes approximately 15% of sporadic CRC and 5% of Stage IV CRC, while MSS CRC composes the remainder.
- ORR immune-related objective response rate
- Metastatic colorectal cancer is characterized by an immunosuppressive environment created by suppressive cell types, such as myeloid-derived suppressor cells (MDSCs) and macrophages. Macrophages can either be tumor fighting (Ml-subtype) or tumor helping (M2-subtype). In CRC, macrophages within the tumor (tumor-associated macrophages [TAMs]) are often of the tumor promoting M2-subtype.
- TAMs tumor-associated macrophages
- One of the master switches for determining whether a macrophage is tumor promoting (M2-subtype) versus tumor fighting (Ml-subtype) is the CCR5 receptor.
- the G-protein-coupled receptor, CCR5, and its chemokine ligands (CCL3, CCL4, and CCL5) induce recruitment of stromal and
- T cells at the invasive margins of human CRC liver metastases produce CCL5, which has tumor-promoting effects on tumor cells and TAMs (M2-subtype).
- MIF macrophage migration inhibitory factor
- IFN-a interferon alfa
- IFN-a2a interferon alfa-2a
- CCR5-CCL5 signaling promotes the homing of immunosuppressive regulatory T cells (Tregs) in CRC and pancreatic cancer, and disruption of this signaling results in decreased migration of Tregs into the tumor and reduced tumor growth.
- Tregs immunosuppressive regulatory T cells
- CCR5 and its ligands can also be expressed on T cells and NK (natural killer) cells. Studies are underway to better understand how inhibition of this axis balances the immune milieu to prevent cancer dissemination and to destroy tumor cells.
- CCR5 can also be expressed on tumor cells and in the stroma by cancer-associated fibroblasts.
- CCR5 is highly expressed by mCRC tumor cells, and CCR5 blockade can induce cytotoxic and apoptotic effects in CRC cancer cells (Weitzenfeld P, Ben-Baruch A.,“The Chemokine System, and its CCR5 and CXCR4 receptors, as Potential Targets for Personalized Therapy in Cancer,” Cancer Lett. 2014 Sep 28;352(l):36-53).
- CCR5 antagonism has been shown to impact tumor progression and metastases in several tumor types (eg, gastric, breast, prostate) in nonclinical studies using xenograft models (Velasco-Velazquez, M., et ah,“CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells,” Cancer Res. 2012 Aug l;72(l5):3839-50; Ochoa-Callejero, L., et ah,“Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model,” PLoS One.
- CCR5 antagonism might reverse tumor immune suppression causedby immune suppressive cell populations in the tumor microenvironment, such as MDSCs, Tregs, and TAMs. Reversal of this immunosuppression may allow immune checkpoint inhibitors (eg, PDL-l antagonists) to be more effective against CRC, as well os other types of cancer.
- immune checkpoint inhibitors eg, PDL-l antagonists
- the invention provides a method of treating a cell proliferation disorder, e.g ., cancer, comprising administering:
- the cell proliferation disorder is cancer
- the cancer is microsatellite stable (MSS) colorectal cancer (CRC), prostate cancer, pancreatic cancer, melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, non-Hodgkin lymphoma, renal cancer, Hodgkin lymphoma,
- MSS microsatellite stable
- CRC colorectal cancer
- NSCLC non-small cell lung cancer
- head and neck cancer urothelial cancer
- breast cancer gastrointestinal cancer
- multiple myeloma hepatocellular cancer
- non-Hodgkin lymphoma renal cancer
- Hodgkin lymphoma Hodgkin lymphoma
- the cancer expresses PD-L1, such as cancers having tumors with a PD-L1 tumor proportion score (TPS) of >1% , >10% or >50%or a PD-L1 combined positive score (CPS) of >1 or >10.
- TPS tumor proportion score
- CPS combined positive score
- the level of PD-L1 TPS is determined by an FDA-approved test.
- the cancer is melanoma, NSCLC, head and neck squamous cell cancer (HNSCC), Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, Merkel cell carcinoma, hepatocellular carcinoma or cervical cancer.
- HNSCC head and neck squamous cell cancer
- the cancer is colorectal cancer (CRC).
- CRC colorectal cancer
- the colorectal cancer is microsatellite stable (MSS) colorectal cancer (CRC).
- MSS microsatellite stable colorectal cancer
- the microsatellite stable colorectal cancer is advanced microsatellite stable colorectal cancer or metastatic microsatellite stable colorectal cancer.
- the cancer is pancreatic cancer.
- the cancer is microsatellite stable colorectal cancer.
- the CCR5 antagonist is vicriviroc maleate.
- the human patient is administered:
- anti-human PD-l antibody or antigen binding fragment thereof is administered once every two-six weeks and the vicriviroc maleate is administered once daily.
- the human patient is administered 200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and 150 mg of vicriviroc maleate; wherein the anti-human PD- 1 antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily.
- the human patient is administered 200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and 250 mg of vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily.
- the human patient has been previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan, and have received, been intolerant to, or been ineligible for said therapies.
- the invention provides a kit comprising:
- the kit further comprises instructions for administering vicriviroc maleate and the anti-human PD-l antibody or antigen binding fragment thereof to a human patient.
- the invention provides a therapeutic combination, comprising: (a) vicriviroc maleate; and
- an anti-human PD-l antibody or antigen binding fragment thereof for treating a cell proliferation disorder e.g. , cancer, in a human patient.
- the anti-human PD-l antibody or antigen binding fragment thereof comprises three light chain CDRs of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3 and three heavy chain CDRs of SEQ ID NO:6, SEQ ID NO: 7 and SEQ ID NO:8.
- the anti-human PD-l antibody or antigen binding fragment thereof comprises a VL region which comprises the amino acid sequence set forth in SEQ ID NO:4, and a VH region which comprises the amino acid sequence set forth in SEQ ID NO:9.
- the anti-human PD-l antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO: 10.
- the anti-human PD-l antibody or antigen binding fragment thereof is pembrolizumab.
- the anti-human PD-l antibody or antigen binding fragment thereof is nivolumab.
- FIGURE 1 shows CCR5 expression in human tumors.
- FIGURE 2 shows the in vitro activity of vicriviroc on MV-4-11 Tumor Cell
- FIGURE 3 shows that vicriviroc enhances antigen-specific IFN-g responses to pembrolizumab oh rhesus monkey T cells.
- T/C Median tumor volume of the treated animal/Median tumor volume of the control animal
- “About” when used to modify a numerically defined parameter means that the parameter may vary by as much as 10% below or above the stated numerical value for that parameter; where appropriate, the stated parameter may be rounded to the nearest whole number. For example, a dose of about 5 mg/kg may vary between 4.5 mg/kg and 5.5 mg/kg.
- antibody refers to any form of immunoglobulin molecule that exhibits the desired biological or binding activity. Thus, it is used in the broadest sense and specifically covers, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized, fully human antibodies, and chimeric antibodies.“Parental antibodies” are antibodies obtained by exposure of an immune system to an antigen prior to modification of the antibodies for an intended use, such as humanization of an antibody for use as a human therapeutic.
- antibody encompasses not only intact polyclonal or monoclonal antibodies, but also, unless otherwise specified, any antigen binding portion thereof that competes with the intact antibody for specific binding, fusion proteins comprising an antigen binding portion, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site.
- the basic antibody structural unit comprises a tetramer.
- Each tetramer includes two identical pairs of polypeptide chains, each pair having one "light” (about 25 kDa) and one "heavy” chain (about 50-70 kDa).
- the amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the variable regions of each light/heavy chain pair form the antibody binding site.
- an intact antibody has two binding sites.
- the carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function.
- human light chains are classified as kappa and lambda light chains.
- human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
- the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 10 more amino acids. See generally,
- “antibody fragment” or“antigen binding fragment” refers to a fragment of an antibody that retains the ability to bind specifically to the antigen, e.g ., fragments that retain one or more CDR regions.
- An antibody that “specifically binds to” PD-l or PD-L1 is an antibody that exhibits preferential binding to PD-l or PD-L1 (as appropriate) as compared to other proteins, but this specificity does not require absolute binding specificity.
- An antibody is considered“specific” for its intended target if its binding is determinative of the presence of the target protein in a sample, e.g. , without producing undesired results such as false positives.
- Antibodies, or binding fragments thereof, will bind to the target protein with an affinity that is at least two fold greater, preferably at least ten times greater, more preferably at least 20-times greater, and most preferably at least lOO-times greater than the affinity with non-target proteins.
- Antigen binding portions include, for example, Fab, Fab’, F(ab’)2, Fd, Fv, fragments including complementarity determining regions (CDRs), and single chain variable fragment antibodies (scFv), and polypeptides that contain at least a portion of an
- immunoglobulin that is sufficient to confer specific antigen binding to the PD-l or PD-L1.
- An antibody includes an antibody of any class, such as IgG, IgA, or IgM (or sub-class thereof), and the antibody need not be of any particular class.
- immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g, IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.
- the heavy-chain constant regions that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
- the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
- the terms“at least one” item or“one or more” item each include a single item selected from the list as well as mixtures of two or more items selected from the list.
- immune response relates to any one or more of the following: specific immune response, non-specific immune response, both specific and non specific response, innate response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell-proliferation, immune cell differentiation, and cytokine expression.
- pharmaceutically acceptable carrier refers to any inactive substance that is suitable for use in a formulation for the delivery of a therapeutic agent.
- a carrier may be an antiadherent, binder, coating, disintegrant, filler or diluent, preservative (such as antioxidant, antibacterial, or antifungal agent), sweetener, absorption delaying agent, wetting agent, emulsifying agent, buffer, and the like.
- Suitable pharmaceutically acceptable carriers include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), dextrose, vegetable oils (such as olive oil), saline, buffer, buffered saline, and isotonic agents such as sugars, polyalcohols, sorbitol, and sodium chloride.
- the term“subject” refers to a mammal that has been the object of treatment, observation, or experiment.
- the mammal may be male or female.
- the mammal may be one or more selected from the group consisting of humans, bovine (e.g, cows), porcine (e.g, pigs), ovine (e.g, sheep), capra (e.g, goats), equine (e.g, horses), canine (e.g, domestic dogs), feline (e.g, house cats), Lagomorpha (rabbits), rodents (e.g, rats or mice), Procyon lotor (e.g, raccoons).
- the subject is human.
- subject in need thereof refers to a subject diagnosed with, or suspected of having, a cell-proliferation disorder, such as a cancer, as defined herein.
- treatment and“treating” refer to all processes in which there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of a disease or disorder described herein.
- the terms do not necessarily indicate a total elimination of all disease or disorder symptoms.
- variable regions or“V region” or“V chain” as used herein means the segment of IgG chains which is variable in sequence between different antibodies.
- A“variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination.
- the variable regions of both the heavy and light chains comprise three hypervariable regions, also called complementarity determining regions (CDRs), which are located within relatively conserved framework regions (FR).
- CDRs complementarity determining regions
- FR relatively conserved framework regions
- the CDRs are usually aligned by the framework regions, enabling binding to a specific epitope.
- both light and heavy chains variable domains comprise FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
- Chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain contains sequences derived from a particular species (e.g ., human) or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is derived from another species (e.g., mouse) or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
- a particular species e.g ., human
- another species e.g., mouse
- Human antibody refers to an antibody that comprises human immunoglobulin protein sequences or derivatives thereof.
- a human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell.
- “mouse antibody” or“rat antibody” refer to an antibody that comprises only mouse or rat immunoglobulin sequences or derivatives thereof, respectively.
- Humanized antibody refers to forms of antibodies that contain sequences from non-human (e.g, murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human
- the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
- Fc immunoglobulin constant region
- the prefix“hum”,“hu” or“h” may be added to antibody clone designations when necessary to distinguish humanized antibodies from parental rodent antibodies.
- the humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.
- Biotherapeutic agent means a biological molecule, such as an antibody or fusion protein, that blocks ligand/receptor signaling in any biological pathway that supports tumor maintenance and/or growth or suppresses the anti-tumor immune response.
- “Chemotherapeutic agent” refers to a chemical or biological substance that can cause death of cancer cells, or interfere with growth, division, repair, and/or function of cancer cells. Examples of chemotherapeutic agents include those that are disclosed in WO2006/129163, and US20060153808. Classes of chemotherapeutic agents include, but are not limited to:
- alkylating agents antimetabolites, kinase inhibitors, spindle poison, plant alkaloids,
- cytoxic/antitumor antibiotics topisomerase inhibitors, photosensitizers, anti-estrogens and selective estrogen receptor modulators (SERMs), anti-progesterones, estrogen receptor down- regulators (ERDs), estrogen receptor antagonists, leutinizing hormone-releasing hormone agonists, anti-androgens, aromatase inhibitors, EGFR inhibitors, VEGF inhibitors, and anti-sense oligonucleotides that inhibit expression of genes implicated in abnormal cell-proliferation or tumor growth.
- Chemotherapeutic agents useful in the treatment methods of the present disclosure include cytostatic and/or cytotoxic agents.
- enteral route refers to the administration via any part of the gastrointestinal tract.
- enteral routes include oral, mucosal, buccal, and rectal route, or intragastric route.
- Parenteral route refers to a route of administration other than enteral route.
- parenteral routes of administration examples include intravenous, intramuscular, intradermal, intraperitoneal, intratumor, intravesical, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, transtracheal, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal, subcutaneous, or topical administration.
- the therapeutic agents and compositions of the disclosure can be administered using any suitable method, such as by oral ingestion, nasogastric tube, gastrostomy tube, injection, infusion, implantable infusion pump, and osmotic pump.
- the suitable route and method of administration may vary depending on a number of factors such as the specific therapeutic agent being used, the rate of absorption desired, specific formulation or dosage form used, type or severity of the disorder being treated, the specific site of action, and conditions of the patient, and can be readily selected by a person skilled in the art.
- simultaneous administration refers to the administration of medicaments such that the individual medicaments are present within a subject at the same time.
- simultaneous administration may include the administration of the medicaments (via the same or an alternative route) at different times.
- Chothia as used herein means an antibody numbering system described in Al- Lazikani et al. , JMB 273:927-948 (1997).
- Constantly modified variants or“conservative substitution” refers to substitutions of amino acids in a protein with other amino acids having similar characteristics (e.g ., charge, side-chain size, hydrophobicity/hydrophilicity, backbone conformation and rigidity, etc.), such that the changes can frequently be made without altering the biological activity or other desired property of the protein, such as antigen affinity and/or specificity.
- Consists essentially of and variations such as“consist essentially of’ or “consisting essentially of,” as used throughout the specification and claims, indicate the inclusion of any recited elements or group of elements, and the optional inclusion of other elements, of similar or different nature than the recited elements, that do not materially change the basic or novel properties of the specified dosage regimen, method, or composition.
- Diagnostic anti-PD-L monoclonal antibody means a mAh that specifically binds to the mature form of the designated PD-L (PD-L1 or PD-L2) expressed on the surface of certain mammalian cells.
- a mature PD-L lacks the presecretory leader sequence, also referred to as leader peptide.
- the terms“PD-L” and“mature PD-L” are used interchangeably herein, and shall be understood to mean the same molecule unless otherwise indicated or readily apparent from the context.
- a diagnostic anti-human PD-L1 mAh or an anti-hPD-Ll mAh refers to a monoclonal antibody that specifically binds to mature human PD-L1.
- a mature human PD-L1 molecule consists of amino acids 19-290 set forth in SEQ ID NO 21 (Table 3).
- diagnostic anti-human PD-L1 mAbs useful as diagnostic mAbs for IHC detection of PD-L1 expression in FFPE tumor tissue sections are antibodies 20C3 and 22C3, which are described in PCT International Patent Application Publication No.
- the CPS is useful in selecting patients for treatment with particular treatment regimens including methods of treatment comprising administration of an anti-PD-l antibody in which expression of PD-L1 is associated with a higher response rate in a particular patient population relative to same patient population that does not express PD-L1.
- the CPS is determined by determining the number of viable PD-L1 positive tumor cells, the number of viable PD-L1 negative tumor cells, and the number of viable PD-L1 positive mononuclear inflammatory cells (MIC) in a tumor tissue from a patient having a tumor and calculating the CPS using the following formula:
- TPS tumor proportion score
- TPS typically includes the percentage of neoplastic cells expressing PD-L1 at any intensity (weak, moderate, or strong), which can be determining using an immunohistochemical assay using a diagnostic anti-human PD-L1 mAb, e.g. antibody 20C3 and antibody 22C3, described, supra.
- Cells are considered to express PD-L1 if membrane staining is present, including cells with partial membrane staining.
- “Homology” refers to sequence similarity between two polypeptide sequences when they are optimally aligned. When a position in both of the two compared sequences is occupied by the same amino acid monomer subunit, e.g., if a position in a light chain CDR of two different Abs is occupied by alanine, then the two Abs are homologous at that position.
- the percent of homology is the number of homologous positions shared by the two sequences divided by the total number of positions compared c 100. For example, if 8 of 10 of the positions in two sequences are matched when the sequences are optimally aligned then the two sequences are 80% homologous.
- the comparison is made when two sequences are aligned to give maximum percent homology. For example, the comparison can be performed by a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences.
- BLAST ALGORITHMS Altschul, S.F., et al, (1990) J. Mol. Biol. 215:403-410; Gish, W., et al., (1993) Nature Genet. 3:266-272; Madden, T.L., et al, (1996) Meth. Enzymol.
- isolated refers to the purification status and, in such context, means the named molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term“isolated” is not intended to refer to a complete absence of such material or to an absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with experimental or therapeutic use of the binding compound as described herein.
- Kabat (1991) Sequences of Proteins of Immunological Interest
- “Monoclonal antibody” or“mAh” or“Mab”, as used herein, refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts.
- conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains, particularly their CDRs, which are often specific for different epitopes.
- the modifier“monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see, e.g, U.S. Pat. No. 4,816,567).
- The“monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson el al. (1991) Nature 352: 624-628 and Marks et al. (1991) J Mol. Biol. 222: 581-597, for example. See also Presta (2005) J. Allergy Clin. Immunol. 116:731.
- RECIST 1.1 Response Criteria as used herein means the definitions set forth in Eisenhauer, E.A. et al., Eur. J. Cancer 45:228-247 (2009) for target lesions or nontarget lesions, as appropriate based on the context in which response is being measured.
- sustained response means a sustained therapeutic effect after cessation of treatment as described herein.
- the sustained response has a duration that is at least the same as the treatment duration, or at least 1.5, 2.0, 2.5 or 3 times longer than the treatment duration.
- tissue Section refers to a single part or piece of a tissue, e.g. , a thin slice of tissue cut from a sample of a normal tissue or of a tumor.
- “Treat” or“treating” a cell-proliferation disorder as used herein means to administer a combination therapy of an anti-human PD-l antibody (or antigen binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, to a subject having a cell- proliferation disorder, such as cancer, or diagnosed with a cell-proliferation disorder, such as cancer, to achieve at least one positive therapeutic effect, such as for example, reduced number of cancer cells, reduced tumor size, reduced rate of cancer cell infiltration into peripheral organs, or reduced rate of tumor metastasis or tumor growth.
- Such“treatment” may result in a slowing, interrupting, arresting, controlling, or stopping of the progression of a cell-proliferation disorder as described herein but does not necessarily indicate a total elimination of the cell-proliferation disorder or the symptoms of the cell-proliferation disorder.
- Positive therapeutic effects in cancer can be measured in a number of ways (See, W. A. Weber, J. Nucl. Med. 50: lS-l0S (2009)). For example, with respect to tumor growth inhibition, according to NCI standards, a T/C £ 42% is the minimum level of anti -tumor activity.
- the treatment achieved by a combination therapy of the disclosure is any of PR, CR, OR, PFS, DFS, and OS.
- PFS also referred to as“Time to Tumor Progression” indicates the length of time during and after treatment that the cancer does not grow, and includes the amount of time patients have experienced a CR or PR, as well as the amount of time patients have experienced SD.
- DFS refers to the length of time during and after treatment that the patient remains free of disease.
- OS refers to a prolongation in life expectancy as compared to naive or untreated individuals or patients.
- response to a combination therapy of the disclosure is any of PR, CR, PFS, DFS, or OR that is assessed using RECIST 1.1 response criteria.
- the treatment regimen for a combination therapy of the disclosure that is effective to treat a cancer patient may vary according to factors such as the disease state, age, and weight of the patient, and the ability of the therapy to elicit an anti-cancer response in the subject.
- any of the aspects of the disclosure may not be effective in achieving a positive therapeutic effect in every subject, it should do so in a statistically significant number of subjects as determined by any statistical test known in the art such as the Student’ s t-test, the chi 2 -test, the U-test according to Mann and Whitney, the Kruskal -Wallis test (H-test), Jonckheere-Terpstra-test and the Wilcoxon-test.
- any statistical test known in the art such as the Student’ s t-test, the chi 2 -test, the U-test according to Mann and Whitney, the Kruskal -Wallis test (H-test), Jonckheere-Terpstra-test and the Wilcoxon-test.
- the terms“combination therapy” and“therapeutic combination” refer to treatments in which at least one anti -human PD-l antibody (or antigen-binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, and optionally additional therapeutic agents, each are administered to a patient in a coordinated manner, over an overlapping period of time.
- the period of treatment with the at least one anti -human PD-l antibody (or antigen-binding fragment thereof) is the period of time that a patient undergoes treatment with the anti-human PD-l antibody (or antigen-binding fragment thereof); that is, the period of time from the initial dosing with the anti-human PD-l antibody (or antigen-binding fragment thereof) through the final day of a treatment cycle.
- the period of treatment with vicriviroc, or a pharmaceutically acceptable salt thereof is the period of time that a patient undergoes treatment with vicriviroc, or a pharmaceutically acceptable salt thereof; that is, the period of time from the initial dosing with vicriviroc, or a pharmaceutically acceptable salt thereof, through the final day of a treatment cycle.
- the anti-PD- 1 treatment overlaps by at least one day the vicriviroc treatment.
- the anti -PD-l treatment and the vicriviroc treatment are coextensive.
- the anti -PD-l treatment begins prior to the vicriviroc treatment.
- the vicriviroc treatment begins prior to the anti-PD-l treatment. In embodiments, the anti-PD-l treatment is terminated prior to termination of vicriviroc treatment. In embodiments, the vicriviroc treatment is terminated prior to termination of the anti-PD-l treatment.
- treatment regimen “dosing protocol”, and“dosing regimen” are used interchangeably to refer to the dose and timing of administration of each therapeutic agent in a combination therapy of the disclosure.
- Tumor as it applies to a subject diagnosed with, or suspected of having, a cancer refers to a malignant or potentially malignant neoplasm or tissue mass of any size, and includes primary tumors and secondary neoplasms.
- a solid tumor is an abnormal growth or mass of tissue that usually does not contain cysts or liquid areas. Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors (National Cancer Institute, Dictionary of Cancer Terms).
- Advanced solid tumor malignancy and“advanced solid tumor” are used interchangeably to refer to a tumor for which curative resection is not possible.
- Advanced solid tumors include, but are not limited to, metastatic tumors in bone, brain, breast, liver, lungs, lymph node, pancreas, prostate, and soft tissue (sarcoma).
- Tumor burden also referred to as“tumor load”, refers to the total amount of tumor material distributed throughout the body. Tumor burden refers to the total number of cancer cells or the total size of tumor(s), throughout the body, including lymph nodes and bone narrow. Tumor burden can be determined by a variety of methods known in the art, such as, e.g ., by measuring the dimensions of tumor(s) upon removal from the subject, e.g. , using calipers, or while in the body using imaging techniques, e.g. , ultrasound, bone scan, computed tomography (CT) or magnetic resonance imaging (MRI) scans.
- CT computed tomography
- MRI magnetic resonance imaging
- tumor size refers to the total size of the tumor which can be measured as the length and width of a tumor. Tumor size may be determined by a variety of methods known in the art, such as, e.g. , by measuring the dimensions of tumor(s) upon removal from the subject, e.g. , using calipers, or while in the body using imaging techniques, e.g. , bone scan, ultrasound, CT or MRI scans.
- imaging techniques e.g. , bone scan, ultrasound, CT or MRI scans.
- a range of 3 to 7 days is intended to include 3, 4, 5, 6, and 7 days.
- the term "or,” as used herein, denotes alternatives that may, where appropriate, be combined; that is, the term “or” includes each listed alternative separately as well as their combination.
- the present disclosure relates to methods of treating a cell-proliferation disorder as defined herein, wherein the method comprises administering to a human patient in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody, or antigen binding fragment thereof; and (b) vicriviroc, or a pharmaceutically acceptable salt thereof.
- the present disclosure also relates to a therapeutic combination, wherein the therapeutic combination comprises (a) an anti-human PD-l antibody, or antigen-binding fragment thereof; and (b) vicriviroc, or a pharmaceutically acceptable salt thereof.
- the anti human PD-l antibody is pembrolizumab.
- the invention provides therapeutic combinations comprising antibodies or antigen binding fragments thereof, which specifically bind to human PD-l (e.g ., a human or humanized anti -PD- 1 antibody) and vicriviroc, or a pharmaceutically acceptable salt thereo, as well as methods for using the therapeutic combinations of the invention.
- human PD-l e.g ., a human or humanized anti -PD- 1 antibody
- vicriviroc e.g., a human or humanized anti -PD- 1 antibody
- a pharmaceutically acceptable salt thereo e.g a human or humanized anti -PD- 1 antibody
- Any anti-human PD-l antibody or antigen binding fragment thereof can be used in the therapeutic combinations and methods of the invention.
- the anti-human PD-l antibody is selected from pembrolizumab and nivolumab.
- the anti-human PD-l antibody is pembrolizumab.
- the anti-human PD-l antibody is nivolumab
- Table 2 provides amino acid sequences for exemplary anti-human PD-l antibodies
- an anti-human PD-l antibody or antigen binding fragment thereof for use in the therapeutic combinations and methods of the invention comprises three light chain CDRs of CDRL1, CDRL2 and CDRL3 and/or three heavy chain CDRs of CDRH1, CDRH2 and CDRH3.
- CDRL1 is SEQ ID NO: 1 or a variant of SEQ ID NO: 1
- CDRL2 is SEQ ID NO:2 or a variant of SEQ ID NO:2
- CDRL3 is SEQ ID NO:3 or a variant of SEQ ID NO:3.
- CDRH1 is SEQ ID NO:6 or a variant of SEQ ID NO:6,
- CDRH2 is SEQ ID NO: 7 or a variant of SEQ ID NO:7
- CDRH3 is SEQ ID NO:8 or a variant of SEQ ID NO:8.
- the three light chain CDRs are SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO: 3 and the three heavy chain CDRs are SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO:8.
- CDRL1 is SEQ ID NO: 11 or a variant of SEQ ID NO: 11
- CDRL2 is SEQ ID NO: 12 or a variant of SEQ ID NO: 12
- CDRL3 is SEQ ID NO: 13 or a variant of SEQ ID NO: 13.
- CDRH1 is SEQ ID NO: 16 or a variant of SEQ ID NO: 16
- CDRH2 is SEQ ID NO: 17 or a variant of SEQ ID NO: 17
- CDRH3 is SEQ ID NO: 18 or a variant of SEQ ID NO: 18.
- the three light chain CDRs are SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13 and the three heavy chain CDRs are SEQ ID NO:
- Some antibody and antigen binding fragments used in the therapeutic combinations and methods of the invention comprise a light chain variable region and a heavy chain variable region.
- the light chain variable region comprises SEQ ID NO:4 or a variant of SEQ ID NO:4, and the heavy chain variable region comprises SEQ ID NO:9 or a variant of SEQ ID NO:9.
- the light chain variable region comprises SEQ ID NO: 14 or a variant of SEQ ID NO: 14, and the heavy chain variable region comprises SEQ ID NO: 19 or a variant of SEQ ID NO: 19.
- a variant light chain or heavy chain variable region sequence is identical to the reference sequence except having one, two, three, four or five amino acid substitutions.
- the substitutions are in the framework region (i.e., outside of the CDRs).
- one, two, three, four or five of the amino acid substitutions are conservative substitutions.
- the antibody or antigen binding fragment comprises a light chain variable region comprising or consisting of SEQ ID NO:4 and a heavy chain variable region comprising or consisting SEQ ID NO:9.
- the antibody or antigen binding fragment comprises a light chain variable region comprising or consisting of SEQ ID NO: 14 and a heavy chain variable region comprising or consisting of SEQ ID NO: 19.
- the therapeutic combinations and methods of the invention comprise an antibody or antigen binding protein that has a VL domain and/or a VH domain with at least 98%, 95%, 90%, 85%, 80%, 75% or 50% sequence homology to one of the VL domains or VH domains described above, and exhibits specific binding to PD-l .
- the antibody or antigen binding protein of the therapeutic combinations and methods of the invention comprises VL and VH domains having up to 1, 2, 3, 4, or 5 or more amino acid substitutions, and exhibits specific binding to PD-l.
- the amino acid substitutions are conservative substitutions.
- the therapeutic combinations and methods may use a full-length anti -PD-l antibody or an antigen binding fragment thereof that specifically binds human PD-l.
- a full-length anti-human PD-l antibody selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE is used.
- the antibody is an IgG antibody. Any isotype of IgG can be used, including IgGi, IgG2, IgG3, and IgG 4. Different constant domains may be appended to the VL and VH regions provided herein.
- a heavy chain constant domain other than IgGl may be used.
- IgGl antibodies provide for long half-life and for effector functions, such as complement activation and antibody-dependent cellular cytotoxicity, such activities may not be desirable for all uses of the antibody.
- an IgG4 constant domain for example, may be used.
- the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:5 or a variant of SEQ ID NO:5, and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 10, or a variant of SEQ ID NO: 10.
- an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:5 or a variant of SEQ ID NO:5, and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 10, or a variant of SEQ ID NO: 10.
- the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:5 or a variant of SEQ ID NO:5, and a heavy chain comprising or
- an anti -human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 15, or a variant of SEQ ID NO: 15, and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:20, or a variant of SEQ ID NO: 15.
- the variant of SEQ ID NO:5, 10, 15 or 20 has up to 1, 2, 3, 4, 5, 6, 7, 8 or 9 conservative amino acid substitutions.
- the variant of SEQ ID NO:5, 10, 15, or 20 has a C-terminal deletion/truncation of 1, 2, 3, 4, or 5 amino acids.
- the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 10.
- the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 15 and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:20.
- the anti-human PD-l antibody is pembrolizumab or a pembrolizumab biosimilar. In some therapeutic combinations and methods of the invention, the anti-human PD-l antibody is nivolumab or a nivolumab biosimilar.
- amino acid sequence variants of the anti -PD-l antibodies and antigen binding fragments used in the invention will have an amino acid sequence having at least 75% amino acid sequence identity with the amino acid sequence of a reference antibody or antigen binding fragment (e.g ., heavy chain, light chain, VH, VL, or humanized sequence), more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95, 98, or 99%.
- a reference antibody or antigen binding fragment e.g ., heavy chain, light chain, VH, VL, or humanized sequence
- Identity or homology with respect to a sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the anti -PD-l residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence shall be construed as affecting sequence identity or homology.
- Sequence identity refers to the degree to which the amino acids of two
- polypeptides are the same at equivalent positions when the two sequences are optimally aligned.
- Sequence identity can be determined using a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences.
- the following references relate to BLAST algorithms often used for sequence analysis: BLAST ALGORITHMS: Altschul, S.F., et al ., (1990) J. Mol. Biol. 215:403-410; Gish, W., et al. , (1993) Nature Genet. 3:266-272; Madden, T.L., et al, (1996) Meth. Enzymol.
- PD-L1 expression expression as used herein means any detectable level of expression of the designated PD-L protein on the cell surface or of the designated PD-L mRNA within a cell or tissue.
- PD-L protein expression may be detected with a diagnostic PD-L antibody in an IHC assay of a tumor tissue section or by flow cytometry.
- PD-L protein expression by tumor cells may be detected by PET imaging, using a binding agent (e.g ., antibody fragment, affibody, and the like) that specifically binds to PD-L1.
- a binding agent e.g ., antibody fragment, affibody, and the like
- Techniques for detecting and measuring PD-L mRNA expression include RT-PCR and realtime quantitative RT- PCR.
- One approach employs a simple binary end-point of positive or negative for PD- Ll expression, with a positive result defined in terms of the percentage of tumor cells that exhibit histologic evidence of cell-surface membrane staining.
- a tumor tissue section is counted as positive for PD-L1 expression is at least 1%, and preferably 5% of total tumor cells.
- PD-L1 expression in the tumor tissue section is quantified in the tumor cells as well as in infiltrating immune cells, which predominantly comprise lymphocytes.
- the percentage of tumor cells and infiltrating immune cells that exhibit membrane staining are separately quantified as ⁇ 5%, 5 to 9%, and then in 10% increments up to 100%.
- PD-L1 expression is counted as negative if the score is ⁇ 5% score and positive if the score is > 5%.
- PD-L1 expression in the immune infiltrate is reported as a semi-quantitative measurement called the adjusted inflammation score (AIS), which is determined by multiplying the percent of membrane staining cells by the intensity of the infiltrate, which is graded as none (0), mild (score of 1, rare lymphocytes), moderate (score of 2, focal infiltration of tumor by lymphohistiocytic aggregates), or severe (score of 3, diffuse infiltration).
- AIS adjusted inflammation score
- the level of PD-L1 mRNA expression may be compared to the mRNA expression levels of one or more reference genes that are frequently used in quantitative
- RT-PCR such as ubiquitin C.
- a level of PD-L1 expression (protein and/or mRNA) by malignant cells and/or by infiltrating immune cells within a tumor is determined to be “overexpressed” or“elevated” based on comparison with the level of PD-L1 expression (protein and/or mRNA) by an appropriate control.
- a control PD-L1 protein or mRNA expression level may be the level quantified in nonmalignant cells of the same type or in a section from a matched normal tissue.
- PD-L1 expression in a tumor sample is determined to be elevated if PD-L1 protein (and/or PD-L1 mRNA) in the sample is at least 10%, 20%, 30% , or 50% greater than in the control.
- a CCR5 antagonist useful in the methods and therapeutic compositions of the invention is vicriviroc, or a pharmaceutically acceptable salt thereof.
- Vicriviroc maleate also known as MK-7690, formerly SCH 417690 and SCH-D
- CCR5 antagonist is an orally available small molecule cysteine-cysteine motif chemokine receptor 5 (CCR5) antagonist.
- vicriviroc is l-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-l(R)-[4- (trifluoromethyl)phenyl]ethyl]-3(S)-methyl-l-piperazinyl]-4-methyl-piperidine, 2(Z)- butenedioate(l : 1) and it has the following structure:
- Vicriviroc and it’s activity as a CCR5 antagonist is described in Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W.,“Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Typel” Antimicrob Agents Chemother. 2005 Dec;49(l2):49l 1-9.
- the compounds of the present invention can be employed in the form of pharmaceutically acceptable salts.
- pharmaceutically acceptable salts can be used with compounds for treating patients.
- Non- pharmaceutical salts may, however, be useful in the preparation of intermediate compounds.
- pharmaceutically acceptable salt refers to a salt (including an inner salt such as a zwitterion) that possesses effectiveness similar to the parent compound and that is not biologically or otherwise undesirable (e.g ., is neither toxic nor otherwise deleterious to the recipient thereof).
- an embodiment of the invention provides pharmaceutically acceptable salts of the compounds of the invention.
- salt(s) denotes any of the following: acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
- Salts of compounds of the invention may be formed by methods known to those of ordinary skill in the art, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates,
- benzenesulfonates bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates (“mesylates”), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like.
- Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Additionally, acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al , Camille G. (eds.), Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley - VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould,
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, /-butyl amine, choline, and salts with amino acids such as arginine, lysine and the like.
- alkali metal salts such as sodium, lithium, and potassium salts
- alkaline earth metal salts such as calcium and magnesium salts
- salts with organic bases for example, organic amines
- organic bases for example, organic amines
- salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g, dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g, benzyl and phenethyl bromides), and others.
- lower alkyl halides e.g, methyl, ethyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates e.g, dimethyl, diethyl, and dibutyl sulfates
- long chain halides e.g, decyl, lauryl, and stearyl chlorides,
- Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g, sodium or potassium salts), alkaline earth metal salts (e.g, calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
- suitable pharmaceutically acceptable salts for example, alkali metal salts (e.g, sodium or potassium salts), alkaline earth metal salts (e.g, calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
- suitable pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
- zwitterions when a compound of the invention contains both a basic moiety, such as, but not limited to an aliphatic primary, secondary, tertiary or cyclic amine, an aromatic or heteroaryl amine, pyridine or imidazole, and an acidic moiety, such as, but not limited to tetrazole or carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the terms“salt(s)” as used herein. It is understood that certain compounds of the invention may exist in zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the invention. Administration
- the present disclosure relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof.
- Anti-PD-l antibodies, or antigen-binding fragments thereof may be provided by continuous infusion, or by doses administered, e.g., weekly, bi-weekly, tri -weekly, monthly, bimonthly, every six weeks, etc.
- Doses may be provided, e.g , intravenously, subcutaneously, topically, orally, nasally, intramuscularly, or intratumorally. In certain embodiments, the doses are provided intravenously or subcutaneously.
- a total dose for a treatment interval is generally at least 0.05 pg/kg body weight, more generally at least 0.2 pg/kg, 0.5 pg/kg, 1 pg/kg, 10 pg/kg, 100 pg/kg, 0.25 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, 5.0 mg/kg, 10 mg/kg, 25 mg/kg, 50 mg/kg or more ⁇ see, e.g., Yang, et al. (2003) New Engl. J. Med. 349:427-434, Herold, et al. (2002) New Engl. J. Med. 346: 1692-1698; Liu, et al. (1999) J. Neurol. Neurosurg. Psych.
- Doses may also be provided to achieve a pre-determined target concentration of anti -human PD-l antibody (or antigen-binding fragment thereof) in the subject’s serum, such as 0.1, 0.3, I, 3, 10, 30, 100, 300 pg/mL or more.
- anti-PD-1 antibodies are administered subcutaneously or intravenously, on a weekly, biweekly,“every 4 weeks,” monthly, bimonthly, or quarterly basis at 10, 20, 50, 80, 100, 200, 500, 1000 or 2500 mg/subject.
- the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered as a 200 mg dose once every 21 days. In alternative embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered as a 240 mg dose once every 2 weeks. In other embodiments, the anti -human PD-l antibody (or antigen-binding fragment thereof) is administered as a 400 mg dose once every 6 weeks. In further embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered as a 480 mg dose once every 4 weeks.
- the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered at a dose of 2 mg/kg of a patient’s body weight once even 3 weeks (up to a maximum dose of 200 mg). In still additional embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered at a dose of 3 mg/kg once every 3 weeks.
- the vicriviroc, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient(s) will typically be formulated into a dosage form adapted for administration to a subject by a desired route of administration.
- dosage forms include those adapted for (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral administration, such as sterile solutions, suspensions, and powders for reconstitution.
- oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets
- parenteral administration such as sterile solutions, suspensions, and powders for reconstitution.
- suitable pharmaceutically acceptable carriers or excipients will vary depending upon the particular dosage form chosen.
- suitable pharmaceutically acceptable carriers or excipients may be chosen for a particular function that they may serve in the composition.
- vicriviroc, or a pharmaceutically acceptable salt thereof may be formulated into a dosage form that allows for systemic use, i.e., distribution of vicriviroc, or a pharmaceutically acceptable salt thereof, throughout the body of the subject; examples of such systemic administration include oral administration and intravenous administration.
- vicriviroc, or a pharmaceutically acceptable salt thereof may be formulated into a dosage form that allows for targeted or isolated use, i.e., administration of vicriviroc, or a pharmaceutically acceptable salt thereof, only to the portion of the subject’s body to be treated; examples of such targetted administration include intratumoral injection.
- Vicriviroc or a pharmaceutically acceptable salt thereof, is administered once daily.
- At least one of the therapeutic agents (the anti -PD- 1 antibody, or binding fragment thereof, and vicriviroc, or a pharmaceutically acceptable salt thereof) in the combination therapy is administered using the same dosage regimen (dose, frequency, and duration of treatment) that is typically employed when the agent is used as monotherapy for treating the same condition.
- the patient receives a lower total amount of at least one of the therapeutic agents in the combination therapy than when the agent is used as monotherapy, e.g ., smaller doses, less frequent doses, and/or shorter treatment duration.
- a combination therapy of the invention may be used prior to or following surgery to remove a tumor and may be used prior to, during, or after radiation treatment.
- a combination therapy of the invention is administered to a patient who has not previously been treated with a biotherapeutic or chemotherapeutic agent, i.e., is treatment-naive.
- the combination therapy is administered to a patient who failed to achieve a sustained response after prior therapy with the biotherapeutic or chemotherapeutic agent, i.e., is treatment-experienced.
- the present disclosure relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days or once every six weeks; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
- a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days or once every six weeks; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
- Cell-proliferation disorders include, but are not limited to, cancers, benign papillomatosis, and gestational trophoblastic diseases.
- cancers include, but are not limited to, cancers, benign papillomatosis, and gestational trophoblastic diseases.
- cancers include, but are not limited to, cancers, benign papillomatosis, and gestational trophoblastic diseases.
- cancer “cancer”,“cancerous”, or“malignant” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- cancers where PD-L1 or PD-L2 are implicated may be treated or prevented with a method provided by the disclosure.
- Particularly preferred cancers that may be treated in accordance with the present disclosure include those characterized by elevated expression of one or both of PD-L1 and PD- L2 in tested tissue samples.
- the disease or disorder to be treated is a cell-proliferation disorder.
- the cell-proliferation disorder is cancer.
- the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, metastatic, microsatellite instability-high (MSI- H) cancer, mismatch repair deficient cancer, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary origin (i.e ., cancers in which a metastasized cancer is found but the original cancer site is not known).
- the cancer is AIDS-related.
- the cancer is present in an adult patient; in additional embodiments, the cancer is present in a pediatric patient.
- the invention comprises a method of treating unresectable or metastatic melanoma in a human patient.
- the invention comprises a method for adjuvant therapy of melanoma in a human patient comprising administering a combination therapy of the invention to a patient who has previously had one or more melanoma lesions resected.
- the method comprises treating resected high-risk stage III melanoma.
- the invention comprises a method of treating metastatic non small cell lung cancer (NSCLC) in a human patient.
- NSCLC metastatic non small cell lung cancer
- the NSCLC is non- squamous.
- the NSCLC is squamous.
- the patient has a tumor with high PD-L1 expression [(Tumor Proportion Score (TPS) >50%)] and was not previously treated with platinum-containing chemotherapy.
- TPS Tumor Proportion Score
- the patient has a tumor with PD-L1 expression (TPS >1%) and was previously treated with platinum-containing chemotherapy.
- the patient had disease progression on or after receiving platinum-containing chemotherapy.
- the PD-L1 TPS is determined by an FDA-approved test.
- the patient’s tumor has no EGFR or ALK genomic aberrations.
- the patient’s tumor has an EGFR or ALK genomic aberration and had disease progression on or after receiving treatment for the EGFR or ALK aberration(s) prior to receiving combination therapy of the invention.
- the method further comprises administering pemetrexed and carboplatin to the patient. In some embodiments, the method further comprises administering folic acid and/or vitamin Bi 2 to the patient. In further embodiments, the method further comprises administering dexamethasone to the patient.
- the method further comprises administering carboplatin-paclitaxel or nab-paclitaxel to the patient.
- the invention comprises a method of treating recurrent or metastatic head and neck squamous cell cancer (HNSCC) in a human patient.
- HNSCC head and neck squamous cell cancer
- the patient was previously treated with platinum-containing chemotherapy.
- the patient had disease progression on or after platinum-containing chemotherapy.
- the invention comprises a method of treating refractory classical Hodgkin lymphoma (cHL) in a human patient.
- the patient has relapsed after 1, 2, 3 or more lines of therapy for cHL.
- the patient is an adult patient.
- the patient is a pediatric patient.
- the invention comprises a method of treating locally advanced or metastatic urothelial carcinoma in a human patient.
- the patient is not eligible for cisplatin-containing chemotherapy.
- the patient has disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- the patient’s tumor expresses PD-L1 (CPS > 10).
- the invention comprises a method of treating unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors in a human patient.
- MSI-H microsatellite instability-high
- the patient had disease progression following prior anti-cancer treatment.
- the invention comprises a method of treating unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer in a human patient.
- the patient had disease progression following prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- the invention comprises a method of treating recurrent locally advanced or metastatic gastric cancer or recurrent locally advanced or metastatic
- the patient in a human patient.
- the patient expresses PD-L1 [Combined Positive Score (CPS) >1]
- the patient has disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy.
- the patient has disease progression on or after two or more prior lines of therapy including HER2/neu-targeted therapy.
- the invention comprises a method of treating non-Hodgkin lymphoma in a human patient.
- the non-Hodgkin lymphoma is primary mediastinal large B-cell lymphoma.
- the invention comprises a method of treating cancer in a human patient, wherein the patient has a cancer selected from the group consisting of:
- melanoma non-small cell lung cancer, small cell lung cancer, head and neck cancer, bladder cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, lymphoma, renal cancer, mesothelioma, ovarian cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, and salivary cancer.
- the invention comprises a method of treating Merkel cell carcinoma (MCC) in a human patient.
- MCC Merkel cell carcinoma
- the cancer is recurrent, locally advanced MCC.
- the cancer is metastatic MCC.
- the invention comprises a method of treating hepatocellular carcinoma (HCC) in a human patient.
- HCC hepatocellular carcinoma
- the invention comprises a method of treating renal cell carcinoma (RCC) in a human patient.
- RCC renal cell carcinoma
- the cancer is advanced clear cell RCC.
- the invention comprises a method of treating breast cancer in a human patient in specific embodiments, the breast cancer is triple negative breast cancer. In other specific embodiments, the breast cancer is ER+/HER2- breast cancer.
- the invention comprises a method of treating cancer in a human patient, wherein the cancer is selected from the group consisting of: melanoma, non-small cell lung cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, gastric cancer, cervical cancer, Merkel cell carcinoma, and hepatocellular carcinoma.
- the cancer is selected from the group consisting of: melanoma, non-small cell lung cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, gastric cancer, cervical cancer, Merkel cell carcinoma, and hepatocellular carcinoma.
- the invention comprises a method of treating cancer in a human patient comprising, wherein the patient has a tumor with a high mutational burden.
- the cancer is selected from brain and spinal cancers.
- the brain and spinal cancer is selected from the group consisting of anaplastic astrocytomas, glioblastomas, astrocytomas, and estheosioneuroblastomas (also known as olfactory blastomas).
- the brain cancer is selected from the group consisting of astrocytic tumor (e.g ., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma), oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma), oligoastrocytic tumor (e.g, oligoastrocytoma, and anaplastic
- ependymoma e.g, myxopapillary ependymoma, and anaplastic
- the brain cancer is selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, and suprantentorial primordial neuroectodermal tumors (sPNET).
- the cancer is selected from cancers of the head and neck, including recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), nasopharyngeal cancers, nasal cavity and paranasal sinus cancers, hypopharyngeal cancers, oral cavity cancers ( e.g ., squamous cell carcinomas, lymphomas, and sarcomas), lip cancers, oropharyngeal cancers, salivary gland tumors, cancers of the larynx (e.g., laryngeal squamous cell carcinomas, rhabdomyosarcomas), and cancers of the eye or ocular cancers.
- the ocular cancer is selected from the group consisting of intraocular melanoma and retinoblastoma.
- the cancer is selected from leukemia and cancers of the blood.
- the cancer is selected from the group consisting of myeloproliferative neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), post-MPN AML, post- MDS AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphoma, acute lymphoblastic leukemia, Langerans cell histiocytosis, hairy cell leukemia, and plasma cell neoplasms including plasmacytomas and multiple myelomas.
- Leukemias referenced herein may be acute or chronic.
- the cancer is selected from skin cancers.
- the skin cancer is selected from the group consisting of melanoma, squamous cell cancers, and basal cell cancers.
- the skin cancer is unresectable or metastatic melanoma.
- the cancer is selected from cancers of the reproductive system.
- the cancer is selected from the group consisting of breast cancers, cervical cancers, vaginal cancers, ovarian cancers, endometrial cancers, prostate cancers, penile cancers, and testicular cancers.
- the cancer is a breast cancer selected from the group consisting of ductal carcinomas and phyllodes tumors.
- the breast cancer may be male breast cancer or female breast cancer.
- the breast cancer is triple- negative breast cancer.
- the breast cancer is ER+/HER2- breast cancer.
- the cancer is a cervical cancer selected from the group consisting of squamous cell carcinomas and adenocarcinomas. In specific instances of these embodiments, the cancer is an ovarian cancer selected from the group consisting of epithelial cancers.
- the cancer is selected from cancers of the gastrointestinal system.
- the cancer is selected from the group consisting of esophageal cancers, gastric cancers (also known as stomach cancers),
- the cancer is selected from the group consisting of esophageal squamous cell carcinomas, esophageal adenocarcinomas, gastric adenocarcinomas, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gastric lymphomas, gastrointestinal lymphomas, solid pseudopapillary tumors of the pancreas, pancreatoblastoma, islet cell tumors, pancreatic carcinomas including acinar cell carcinomas and ductal adenocarcinomas, gall bladder adenocarcinomas, colorectal adenocarcinomas, microsatellite stable colorectal cancer, advanced microsatellite stable colorectal cancer, metastatic microsatellite stable colorectal cancer and anal squamous cell carcinomas.
- the cancer is selected from liver and bile duct cancers.
- the cancer is liver cancer (also known as hepatocellular carcinoma).
- the cancer is bile duct cancer (also known as cholangiocarcinoma); in instances of these embodiments, the bile duct cancer is selected from the group consisting of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma.
- the cancer is selected from kidney and bladder cancers.
- the cancer is a kidney cancer selected from the group consisting of renal cell cancer, Wilms tumors, and transitional cell cancers.
- the cancer is a bladder cancer selected from the group consisting of urothelial carcinoma (a transitional cell carcinoma), squamous cell carcinomas, and adenocarcinomas.
- the cancer is selected from bone cancers.
- the bone cancer is selected from the group consisting of osteosarcoma, malignant fibrous histiocytoma of bone, Ewing sarcoma, chordoma (cancer of the bone along the spine).
- the cancer is selected from lung cancers.
- the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancers, bronchial tumors, and pleuropulmonary blastomas.
- the cancer is selected from malignant mesothelioma.
- the cancer is selected from the group consisting of epithelial mesothelioma and sarcomatoids.
- the cancer is selected from sarcomas.
- the sarcoma is selected from the group consisting of central chondrosarcoma, central and periosteal chondroma, fibrosarcoma, clear cell sarcoma of tendon sheaths, and Kaposi's sarcoma.
- the cancer is selected from lymphomas.
- the cancer is selected from the group consisting of Hodgkin lymphoma (e.g ., classical Hodgkin refractory lymphoma), non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mycosis fungoides, Sezary syndrome, primary central nervous system lymphoma), cutaneous T-cell lymphomas, primary central nervous system lymphomas.
- Hodgkin lymphoma e.g ., classical Hodgkin refractory lymphoma
- non-Hodgkin lymphoma e.g., diffuse large B-cell lymphoma, follicular lymphoma, mycosis fungoides, Sezary syndrome, primary central nervous system lymphoma
- cutaneous T-cell lymphomas e.g., primary central nervous system lymphomas.
- the cancer is selected from glandular cancers.
- the cancer is selected from the group consisting of adrenocortical cancer (also known as adrenocortical carcinoma or adrenal cortical carcinoma), pheochromocytomas, paragangliomas, pituitary tumors, thymoma, and thymic carcinomas.
- the cancer is selected from thyroid cancers.
- the thyroid cancer is selected from the group consisting of medullary thyroid carcinomas, papillary thyroid carcinomas, and follicular thyroid carcinomas.
- the cancer is selected from germ cell tumors.
- the cancer is selected from the group consisting of malignant extracranial germ cell tumors and malignant extragonadal germ cell tumors.
- the malignant extragonadal germ cell tumors are selected from the group consisting of nonseminomas and seminomas.
- the cancer is selected from heart tumors.
- the heart tumor is selected from the group consisting of malignant teratoma, lymphoma, rhabdomyosacroma, angiosarcoma, chondrosarcoma, infantile fibrosarcoma, and synovial sarcoma.
- the cell-proliferation disorder is selected from benign papillomatosis, benign neoplastic diseases and gestational trophoblastic diseases.
- the gestational trophoblastic disease is selected from the group consisting of hydati diform moles, and gestational trophoblastic neoplasia ( e.g ., invasive moles,
- choriocarcinomas placental-site trophoblastic tumors, and epithelioid trophoblastic tumors.
- the cell-proliferation disorder is a cancer that has metastasized, for example, a liver metastases from colorectal cancer.
- the cell-proliferation disorder is selected from the group consisting of solid tumors and lymphomas. In particular embodiments, the cell-proliferation disorder is selected from the group consisting of advanced or metastatic solid tumors and lymphomas. In more particular embodiments, the cell-proliferation disorder is selected from the group consisting of malignant melanoma, head and neck squamous cell carcinoma, breast adenocarcinoma, and lymphomas.
- the lymphomas are selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, mediastinal large B-cell lymphoma, splenic marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (malt), nodal marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, primary effusion lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma (primary cutaneous type), anaplastic large cell lymphoma (systemic type), peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T-cell lymphoma/leukemia, nasal type extranodal NK/T-cell lymphoma, enteropathy-associated T-cell lymphoma, gamm
- the cell-proliferation disorder is classified as stage III cancer or stage IV cancer.
- the cancer is not surgically resectable.
- the PD-l antibody or antigen binding fragment can be any anti -PD-l antibody or antigen-binding fragment thereof, including any of the antibodies or antigen-binding fragments described in the section herein entitled“Anti -PD-l Antibodies and Antigen-Binding Fragments Thereof.”
- Products provided as therapeutic combinations may include a composition comprising an anti-human PD-l antibody (or antigen-binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, together in the same pharmaceutical composition, or may include a composition comprising anti -human PD-l antibody (or antigen-binding fragment thereof), and a composition comprising vicriviroc, or a pharmaceutically acceptable salt thereof, in separate form, e.g., in the form of a kit or in any form designed to enable separate administration either concurrently or on separate dosing schedules.
- the combination therapy may also comprise one or more additional therapeutic agents.
- the additional therapeutic agent may be, e.g. , a chemotherapeutic, a biotherapeutic agent (including but not limited to antibodies or antigen-binding fragments thereof that specifically bind to an antigen selected from the group consisting of: PD-L1, PD-L2, CTLA4, LAG3, BTLA, TIM3, HVEM, GITR, CD27, TIGIT, ILT2, ILT3, ILT4, ILT5, SIRPa, NKG2A, NKG2C, NKG2E, TSLP, IL10, VISTA, VEGF, EGFR, Her2/neu, VEGF receptors, other growth factor receptors, CD20, CD28, CD40, CD-40L, CD70, OX-40, 4-1BB, and ICOS).
- a chemotherapeutic including but not limited to antibodies or antigen-binding fragments thereof that specifically bind to an antigen selected from the group consisting of: PD-L1,
- the one or more additional active agents may be co-administered either with the anti-human PD-l antibody (or antigen-binding fragment thereof) or with vicriviroc, or a pharmaceutically acceptable salt thereof.
- the additional active agent(s) may be administered in a single dosage form with one or more co-administered agent selected from the anti -human PD-l antibody (or antigen-binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, or the additional active agent(s) may be administered in separate dosage form(s) from the dosage forms containing the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof.
- the therapeutic combination disclosed herein may be used in combination with one or more other active agents, including but not limited to, other anti-cancer agents that are used in the prevention, treatment, control, amelioration, or reduction of risk of a particular disease or condition (e.g ., cell-proliferation disorders).
- a compound disclosed herein is combined with one or more other anti -cancer agents for use in the prevention, treatment, control amelioration, or reduction of risk of a particular disease or condition for which the compounds disclosed herein are useful.
- Such other active agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present disclosure.
- the additional active agent(s) may be one or more agents selected from the group consisting of STING agonists, poly ADP ribose polymerase (PARP) inhibitors, mitogen- activated protein kinase (MEK) inhibitors, cyclin-dependent kinase (CDK) inhibitors, indoleamine 2,3 -di oxygenase (IDO) inhibitors, tryptophan 2,3 -di oxygenase (TDO) selective inhibitors, anti-viral compounds, antigens, adjuvants, anti-cancer agents, CTLA-4, LAG-3 and PD-l pathway antagonists, lipids, liposomes, peptides, cytotoxic agents, chemotherapeutic agents, immunomodulatory cell lines, checkpoint inhibitors, vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, and immuno
- additional active agents may be overlapping. It will also be understood that the treatment combinations are subject to optimization, and it is understood that the best combination to use of the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or the CXCR2 antagonist, and one or more additional active agents will be determined based on the individual patient needs.
- the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof may be administered either simultaneously with, or before or after, one or more other active agent(s).
- Either of the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).
- the weight ratio of the anti-human PD-l antibody (or antigen-binding fragment thereof) to vicriviroc, or a pharmaceutically acceptable salt thereof may be varied and will depend upon the therapeutically effective dose of each agent. Generally, a therapeutically effective dose of each will be used. Combinations including at least one anti -human PD-l antibody (or antigen-binding fragment thereof), vicriviroc, or a pharmaceutically acceptable salt thereof, and other active agents will generally include a therapeutically effective dose of each active agent. In such combinations, the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof, disclosed herein and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent with, or subsequent to the
- this disclosure provides an anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof, and at least one other active agent as a combined preparation for simultaneous, separate or sequential use in therapy.
- the therapy is the treatment of a cell- proliferation disorder, such as cancer.
- the disclosure provides a kit comprising two or more separate pharmaceutical compositions, one of which contains a anti-human PD-l antibody (or antigen binding fragment thereof) and another of which contains vicriviroc, or a pharmaceutically acceptable salt thereof.
- the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
- a kit of this disclosure may be used for administration of different dosage forms, for example, oral and parenteral, for administration of the separate compositions at different dosage intervals, or for titration of the separate compositions against one another.
- a kit of the disclosure typically comprises directions for administration.
- the disclosure also provides the use of vicriviroc, or a pharmaceutically acceptable salt thereof, for treating a cell-proliferation disorder, where the patient has previously ( e.g ., within 24 hours) been treated with an anti-human PD-l antibody (or antigen-binding fragment thereof).
- the disclosure also provides the use of an anti-human PD-l antibody (or antigen-binding fragment thereof) for treating a cell-proliferation disorder, where the patient has previously (e.g., within 24 hours) been treated with vicriviroc, or a pharmaceutically acceptable salt thereof.
- Anti-viral compounds that may be used in combination with the therapeutic combinations disclosed herein include hepatitis B virus (HBV) inhibitors, hepatitis C virus (HCV) protease inhibitors, HCV polymerase inhibitors, HCV NS4A inhibitors, HCV NS5A inhibitors, HCV NS5b inhibitors, and human immunodeficiency virus (HIV) inhibitors.
- HBV hepatitis B virus
- HCV hepatitis C virus
- HCV hepatitis C virus
- HCV hepatitis C virus
- HCV polymerase inhibitors HCV NS4A inhibitors
- HCV NS5A inhibitors HCV NS5b inhibitors
- HCV NS5b inhibitors human immunodeficiency virus
- Antigens and adjuvants that may be used in combination with the therapeutic combinations disclosed herein include B7 costimulatory molecule, interleukin-2, interferon-g, GM-CSF, CTLA-4 antagonists, OX-40/0X-40 ligand, CD40/CD40 ligand, sargramostim, levamisol, vaccinia virus, Bacille Calmette-Guerin (BCG), liposomes, alum, Freund's complete or incomplete adjuvant, detoxified endotoxins, mineral oils, surface active substances such as lipolecithin, pluronic polyols, polyanions, peptides, and oil or hydrocarbon emulsions.
- BCG Bacille Calmette-Guerin
- Adjuvants such as aluminum hydroxide or aluminum phosphate, can be added to increase the ability of the vaccine to trigger, enhance, or prolong an immune response.
- Additional materials such as cytokines, chemokines, and bacterial nucleic acid sequences, like CpG, a toll-like receptor (TLR) 9 agonist as well as additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8, TLR9, including lipoprotein, lipopolysaccharide (LPS), monophosphoryllipid A, lipoteichoic acid, imiquimod, resiquimod, and in addition retinoic acid-inducible gene I (RIG-I) agonists such as poly I:C, used separately or in combination are also potential adjuvants.
- TLR toll-like receptor
- cytotoxic agents examples include, but are not limited to, arsenic trioxide (sold under the tradename TRISENOX®), asparaginase (also known as L-asparaginase, and Erwinia L- asparaginase, sold under the tradenames ELSPAR® and KIDROLASE®).
- Chemotherapeutic agents that may be used in combination with the therapeutic combinations disclosed herein include abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4- methoxyphenyl)benzene sulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L- valyl-L-prolyl- l-Lproline-t-butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3',4'-didehydro-4'deoxy-8'-norvin-caleukoblastine, dinaciclib, docetaxol, doxetaxel,
- cyclophosphamide carboplatin, carmustine, cisplatin, cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine dolastatin, doxorubicin (adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyurea andtaxanes, ifosfamide, liarozole, lonidamine, lomustine, MDV3100, mechlorethamine (nitrogen mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef, streptozocin, mitomycin, methotrexate, taxanes, nilutamide, olaparib, onapristone, paclitaxel, prednimustine, procarbazine, RPR109
- topoisomerase II inhibitors include but are not limited to, etoposide, and teniposide.
- alkylating agents include but are not limited to, 5-azacytidine, decitabine, temozolomide, dactinomycin (also known as actinomycin-D, melphalan, altretamine, carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil,
- cyclophosphamide dacarbazine, altretamine, ifosfamide, procarbazine, mechlorethamine, streptozocin , thiotepa, and pharmaceutically acceptable salts thereof.
- anti-tumor antibiotics include, but are not limited to, doxorubicin, bleomycin , daunorubicin daunorubicin liposomal (daunorubicin citrate liposome),
- anti-metabolites include, but are not limited to, claribine , 5- fluorouracil, 6-thioguanine, pemetrexed (sold under the tradename ALIMTA®), cytarabine (also known as arabinosylcytosine (Ara-C)), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DEPOCYTTM), decitabine (sold under the tradename DACOGEN®), hydroxyurea and fludarabine, floxuridine, cladribine (also known as 2-chlorodeoxyadenosine (2- CdA), methotrexate (also known as amethopterin, methotrexate sodium (MTX)), and pentostatin.
- claribine 5- fluorouracil, 6-thioguanine
- pemetrexed sold under the tradename ALIMTA®
- cytarabine also known as arabinosylcytosine (Ara
- retinoids include, but are not limited to, alitretinoin, tretinoin, isotretinoin, and bexarotene.
- the present disclosure further relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
- a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
- the present disclosure further relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
- a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
- the present disclosure relates to methods of treating a cell- proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the cell-proliferation disorder is cancer.
- the cancer occurs as one or more solid tumors or lymphomas.
- the cancer is selected from the group consisting of advanced or metastatic solid tumors and lymphomas.
- the cancer is selected from the group consisting of malignant melanoma, head and neck squamous cell carcinoma, MSI-H cancer, MMR deficient cancer,, non-small cell lung cancer, urothelial carcinoma, gastric or garoesophageal junction adenocarcinoma, breast adenocarcinoma, and lymphomas.
- the lymphoma is selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, mediastinal large B-cell lymphoma, splenic marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (malt), nodal marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, primary effusion lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma (primary cutaneous type), anaplastic large cell lymphoma (systemic type), peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T-cell lymphoma/leukemia, nasal type extranodal NK/T-cell lymphoma, enteropathy-associated T-cell lymphoma, gamma
- the cell-proliferation disorder is a cancer that has metastasized, for example, a liver metastases from colorectal cancer.
- the cell-proliferation disorder is a cancer is classified as stage III cancer or stage IV cancer. In instances of these embodiments, the cancer is not surgically resectable.
- the anti-human PD-l antibody is an anti -PD-l monoclonal antibody.
- the anti-human PD-l antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, and AMP-224.
- the anti-human PD-l antibody is selected from nivolumab and pembrolizumab.
- the anti-human PD-l antibody is nivolumab.
- the anti-human PD-l antibody is nivolumab.
- the anti-human PD-l antibody is
- the anti-human PD-l antibody (or antigen binding fragment thereof) is administered by intravenous infusion or subcutaneous injection, and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered orally, by intravenous infusion, by intratumoral injection, or by subcutaneous injection.
- the anti-human PD-l antibody (or antigen binding fragment thereof) is administered by intravenous infusion or subcutaneous injection, and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered orally.
- the anti-human PD-l antibody (or antigen binding fragment thereof) is administered prior to administration of thevicriviroc, or a pharmaceutically acceptable salt thereof.
- the vicriviroc, or a pharmaceutically acceptable salt thereof is administered prior to administration of the anti-human PD-l antibody (or antigen binding fragment thereof).
- the anti-human PD-l antibody (or antigen binding fragment thereof) is administered at a dose of 200 mg; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered at a dose of from 150 mg to 250 mg. In aspects of such embodiments, the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered at a dose of 150 mg or 250 mg. Further aspects of the invention, comprise vicriviroc maleate.
- Additional embodiments of the disclosure include the pharmaceutical compositions, combinations, uses and methods set forth in above, wherein it is to be understood that each embodiment may be combined with one or more other embodiments, to the extent that such a combination is consistent with the description of the embodiments. It is further to be understood that the embodiments provided above are understood to include all embodiments, including such embodiments as result from combinations of embodiments.
- Monoclonal, polyclonal, and humanized antibodies can be prepared (see, e.g, Sheperd and Dean (eds.) (2000) Monoclonal Antibodies, Oxford Univ. Press, New York, NY; Kontermann and Dubel (eds.) (2001) Antibody Engineering, Springer- Verlag, New York;
- Animals can be immunized with cells bearing the antigen of interest. Splenocytes can then be isolated from the immunized animals, and the splenocytes can fused with a myeloma cell line to produce a hybridoma (see, e.g, Meyaard et al. (1997) Immunity 7:283-290; Wright et al. (2000) Immunity 13:233-242; Preston et al, supra, Kaithamana et al. (1999) J. Immunol. 163:5157-5164).
- Fluorescent reagents suitable for modifying nucleic acids including nucleic acid primers and probes, polypeptides, and antibodies, for use, e.g. , as diagnostic reagents, are available (Molecular Probesy (2003) Catalogue, Molecular Probes, Inc., Eugene, OR; Sigma- Aldrich (2003) Catalogue, St. Louis, MO).
- CCR5 is expressed by T cells, including tissue-infiltrating lymphocytes and myeloid cells, including macrophages and monocytes. See, Weitzenfeld P, Ben-Baruch A.,“The Chemokine System, and its CCR5 and CXCR4 receptors, as Potential Targets for Personalized Therapy in Cancer,” Cancer Lett. 2014 Sep 28;352(l):36-53.
- CCR5 is known to be an important co-receptor for macrophage-tropic viruses, including HIV, to enter host cells.
- the organs with the most expression are spleen (4.1 reads per kilobase million [RPKM]), lung (2 RPKM), and small intestine (2 RPKM), with all other expression ⁇ 1 RPKM.
- the Moffitt tumor molecular database analysis also shows that CCR5 is detected broadly across multiple human tumor subsets, including triple negative breast cancer, clear cell kidney cancer (renal cell carcinoma), lung adenocarcinoma, cervical cancer, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, squamous cell lung cancer, melanoma, colorectal microsatellite instability (MSI) high, luminal B breast cancer, head and neck cancer, pancreatic adenocarcinoma, luminal A breast cancer, liver cancer, gastric cancer, serous cell ovarian cancer, esophageal adenocarcinoma, uterine/endometrial-MSI high cancer, sarcoma, urothelial bladder cancer, small cell lung cancer, glioblastoma, and prostate cancer.
- triple negative breast cancer clear cell kidney cancer (renal cell carcinoma), lung adenocarcinoma, cervical cancer, human epidermal growth factor receptor 2 (HER2)-positive breast cancer,
- HER2+ human epidermal growth factor receptor 2 positive
- mRNA messenger ribonucleic acid.
- the expression values are quantile normalized, log 10 Affymetrix intensity; these values are shown on the x-axis.
- Values above 0.7 are associated with expression above the limit of detection.
- Vertical bars in each rectangle represent the median value; vertical bars at the end of each dashed line represent the bottom and top quartiles of the distribution for each indication.
- the small crosses represent individual outlier data points.
- Vicriviroc binds to CCR5 with high affinity. See, Strizki JM, Tremblay C, Xu S,
- Vicriviroc inhibited binding of the natural ligand CCL5 to CCR5.
- Vicriviroc also prevented ligand-induced CCR5 signaling, as shown by inhibition of cell migration, calcium flux, and G-protein binding for all 3 natural ligands, CCL5, CCL3, and CCL4:
- CCL cysteine-cysteine motif chemokine ligand
- IC50 half-maximal inhibitory concentration
- Kd dissociation constant
- Ki inhibitory constant
- nM nanomolar.
- Chemotaxis buffer containing CCL5, CCL3, or CCL4 was placed in the bottom well of a ChemoTx plate and filter unit placed over.
- the vicriviroc-pretreated Ba/F3- CCR5 cells were placed on the filter and plates incubated for 2 hours. Cells remaining on the filter were transferred to a separate plate and quantified using the Cell Titer Glow luminescent cell viability kit (Promega).
- c B550 cells were preloaded with Fura 2AM (Sigma) for 1 hour prior to re-suspending in Hanks Balanced Salt Solution (HBSS) with 1% fetal calf serum, and transferring to a cuvette with flux buffer (HBSS, 10 mM HEPES, 1.6 mM calcium chloride). Vicriviroc was added at 0.01, 0.1, or 1.0 mM. Intracellular calcium flux was monitored by the ratio of fluorescence at 340 nm to 380 nm in a LS-50B Luminescence fluorimeter (Perkin Elmer) after the addition of 10 nM
- d CCR5 signaling was assessed by G-protein binding using a scintillation proximity assay (SPA) and membranes from Chinese hamster ovary cells expressing human CCR5.
- SPA scintillation proximity assay
- Membrane-coated SPA beads were incubated with 10 pM guanosine-5 '-diphosphate in the presence or absence of ligand and/or vicriviroc for 1 hour.
- Guanosine-5 '-[g-35 -S] -triphosphate ([35-S]-GTPyS) 0.1 nM was added for 1 hour additional incubation. Reaction mixtures were filtered and
- membranes washed, and membrane-bound [35-S]-GTPyS determined by liquid scintillation counting. Signaling correlates with bound [35-S]-GTPyS.
- MV-4-11 cells are an acute myeloma cell line established from the blast cells of a lO-year-old male with biphenotypic B-myelomonocytic leukemia, and were confirmed to have CCR5 expression using flow cytometry.
- MV-4-11 cells were plated into 96-well ComingTM BioCoatTM Poly-D-Lysine microplates into which media containing either vicriviroc at 0.01, 0.1, 1, or 10 mM, CCL5 at 0.1, 1, 10, or 100 ng/mL, or no treatment had been added. Plates were incubated in the IncuCyte ZoomTM system (Essen Bioscience) at 37°C for 70 to 72 hours, with a 2-hour phase interval and phase channel selection to collect % confluency data. As shown in Figure 2, mean % confluency ⁇ standard deviation from plating (time 0) to 70 hours during exposure to vicriviroc (Panel A) or to CCL5 (Panel B).
- PBMC peripheral blood mononuclear cells
- CMV cytomegalovirus
- Peripheral blood mononuclear cells from 4 rhesus monkeys previously vaccinated with CMV were stimulated ex vivo with inactivated CMV along with a cocktail of 10 or 1 pg/mL pembrolizumab and 10 nM vicriviroc or control for 72 hours.
- Interferon gamma (IFN-g) secretion in the supernatant was analyzed using an immunoassay. Results are shown as mean values of IFN-g in Figure 3. Error bars indicate standard error of the mean.
- Interferon gamma (IFN-g) secretion increased with combination treatment compared with treatment with pembrolizumab alone.
- vicriviroc caused a dose-dependent and comparable increase in CCR5 levels on human and rhesus monkey PBMC.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) vicriviroc, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
Description
TITLE OF THE INVENTION
COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-l) ANTIBODIES AND VICRIVIROC
FIELD OF THE INVENTION
The present invention relates to combination therapies useful for the treatment of of a cell proliferation disorder, such as cancer. In particular, the invention relates to a combination therapy which comprises an antibody that binds to a Programmed Death 1 protein (PD-l) or an antigen binding fragment thereof, and the CCR5 antagonist vicriviroc.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
The sequence listing of the present application is submitted electronically via EFS-Web as an ASCII-formatted sequence listing, with a file name of“24628WOPCT- SEQLIST-31JUL2019”, a creation date of July 31, 2019 and a size of 21.1 KB. This sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
PD-l is recognized as an important player in immune regulation and the maintenance of peripheral tolerance. PD-l is moderately expressed on naive T, B and NKT cells and up-regulated by T/B cell receptor signaling on lymphocytes, monocytes and myeloid cells (Sharpe et al ., The function of programmed cell death 1 and its ligands in regulating
autoimmunity and infection. Nature Immunology (2007); 8:239-245 ).
Two known ligands for PD-l, PD-L1 (B7-H1) and PD-L2 (B7-DC), are expressed in human cancers arising in various tissues. In large sample sets of e.g, ovarian, renal, colorectal, pancreatic, liver cancers and melanoma, it was shown that PD-L1 expression correlated with poor prognosis and reduced overall survival irrespective of subsequent treatment (Dong et al., Nat Med. 8(8):793-800 (2002); Yang et al. Invest Ophthalmol Vis Sci. 49: 2518- 2525 (2008); Ghebeh et al. Neoplasia 8: 190-198 (2006); Hamanishi et al., Proc. Natl. Acad. Sci. USA 104: 3360-3365 (2007); Thompson et al., Cancer 5: 206-211 (2006) ; Nomi et al., Clin. Cancer Research 13:2151-2157 (2007); Ohigashi et al., Clin. Cancer Research 11 : 2947-2953; Inman et al., Cancer 109: 1499-1505 (2007); Shimauchi et al. Int. J. Cancer 121 :2585-2590 (2007); Gao et al. Clin. Cancer Research 15: 971-979 (2009); Nakanishi J. Cancer Immunol Immunother. 56: 1173- 1182 (2007); and Hino et al., Cancer 00: 1-9 (2010)).
Similarly, PD-l expression on tumor infiltrating lymphocytes was found to mark dysfunctional T cells in breast cancer and melanoma (Ghebeh et al, BMC Cancer. 2008 8:5714- 15 (2008); Ahmadzadeh et al., Blood 114: 1537-1544 (2009)) and to correlate with poor prognosis in renal cancer (Thompson et al., Clinical Cancer Research 15: 1757-1761(2007)).
Thus, it has been proposed that PD-L1 expressing tumor cells interact with PD-l expressing T cells to attenuate T cell activation and evasion of immune surveillance, thereby contributing to an impaired immune response against the tumor.
Immune checkpoint therapies targeting the PD-l axis have resulted in groundbreaking improvements in clinical response in multiple human cancers (Brahmer et al., N Engl JMed 2012, 366: 2455-65; Garon et al. N Engl JMed 2015, 372: 2018-28; Hamid et al., N Engl JMed 2013, 369: 134-44; Robert et al., Lancet 2014, 384: 1109-17; Robert et al., N Engl J Med 2015, 372: 2521-32; Robert et al., N Engl J Med 2015, 372: 320-30; Topalian et al., N Engl JMed 2012, 366: 2443-54; Topalian et al., J Clin Oncol 2014, 32: 1020-30; Wolchok et al., N Engl JMed 2013, 369: 122-33). Immune therapies targeting the PD-l axis include monoclonal antibodies directed to the PD-l receptor (KEYTRUDA™ (pembrolizumab), Merck and Co., Inc., Kenilworth, NJ, USA and OPDIVO™ (nivolumab), Bristol-Myers Squibb Company, Princeton, NJ, USA) and also those that bind to the PD-L1 ligand (MPDL3280A; TECENTRIQ™
(atezolizumab), Genentech, San Francisco, CA, USA; IMFINZI™ (durvalumab), AstraZeneca Pharmaceuticals LP, Wilmington, DE; BAVENCIO™ (avelumab), Merck KGaA, Darmstadt, Germany). Both therapeutic approaches have demonstrated anti-tumor effects in numerous cancer types.
It has been proposed that the efficacy of such antibodies might be enhanced if administered in combination with other approved or experimental cancer therapies, e.g, radiation, surgery, chemotherapeutic agents, targeted therapies, agents that inhibit other signaling pathways that are deregulated in tumors, and other immune enhancing agents.
In both men and women, colorectal cancer (“CRC”) is the third most commonly diagnosed type of cancer, and it is a leading cause of cancer-related deaths globally. The
American Cancer Society estimates that approximately 4.6% of men (1 in 22) and 4.2% of women (1 in 24) will be diagnosed with colorectal cancer in their lifetime [American Cancer Society 2017] The global burden of CRC is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030 (* Arnold, M., et al.,“Global Patterns and Trends in Colorectal Cancer Incidence and Mortality,” Gut 2017;66:683-91). The relative survival rate for CRC is 65% at 5 years following diagnosis and 58% at 10 years [American Cancer Society 2017]
CRC is a heterogeneous disease with a number of etiological pathways, including the chromosomal instability (CIN) pathway, the microsatellite instability (MSI) pathway, and CpG island methylator phenotype (CIMP). CRC may be divided via molecular phenotyping into tumors with normal deoxyribonucleic (DNA) mismatch repair (MMR) function and those with DNA MMR deficient (MMR-D). Tumors showing the presence of MSI are classified as MSI-H (microsatellite instability-high), depending on the extent of instability in the markers tested;
whereas tumors without this characteristic are classified as MSS. MSI CRC composes approximately 15% of sporadic CRC and 5% of Stage IV CRC, while MSS CRC composes the remainder. Based on clinical data for pembrolizumab monotherapy, the immune-related objective response rate (ORR) was 0% (0 of 18 patients) for MMR proficient (MMR-P) CRC and 40% (4 of 10 patients) for MMR-D CRC (Le, D. T., et al.,“PD-l Blockade in Tumors with Mismatch-repair Deficiency,” N Engl JMed. 2015 June 25;372(26):2509-20).
Metastatic colorectal cancer (mCRC) is characterized by an immunosuppressive environment created by suppressive cell types, such as myeloid-derived suppressor cells (MDSCs) and macrophages. Macrophages can either be tumor fighting (Ml-subtype) or tumor helping (M2-subtype). In CRC, macrophages within the tumor (tumor-associated macrophages [TAMs]) are often of the tumor promoting M2-subtype. One of the master switches for determining whether a macrophage is tumor promoting (M2-subtype) versus tumor fighting (Ml-subtype) is the CCR5 receptor. The G-protein-coupled receptor, CCR5, and its chemokine ligands (CCL3, CCL4, and CCL5) induce recruitment of stromal and
inflammatory cells and promote immune evasion mechanisms. T cells at the invasive margins of human CRC liver metastases produce CCL5, which has tumor-promoting effects on tumor cells and TAMs (M2-subtype). In CRC explant models and human CRC tumor biopsies, CCR5 blockade led to repolarization of TAMs (Ml-subtype), modulation of chemokines, a reduction of inflammatory cytokines (macrophage migration inhibitory factor [MIF], C-X-C motif ligand 8, interleukin- 1 receptor antagonist, and vascular endothelial growth factor), an increase in interferon alfa (IFN-a) and interferon alfa-2a (IFN-a2a), and redistribution of infiltrating T cells. These alterations in the immune microenvironment could potentially enhance the antitumor effects of antiprogrammed cell death 1 (anti-PD-l) treatment (Halama N, et al.,“Tumoral Immune Cell Exploitation in Colorectal Cancer
Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Pateints,” Cancer Cell. 2016 Apr 1 l;29(4):587-60l). Moreover, CCR5-CCL5 signaling promotes the homing of immunosuppressive regulatory T cells (Tregs) in CRC and pancreatic cancer, and disruption of this signaling results in decreased migration of Tregs into the tumor and reduced tumor growth. In addition to its expression on immunosuppressive cell types such as Tregs, MDSCs, and TAMs, CCR5 and its ligands can also be expressed on T cells and NK (natural killer) cells. Studies are underway to better understand how inhibition of this axis balances the immune milieu to prevent cancer dissemination and to destroy tumor cells. CCR5 can also be expressed on tumor cells and in the stroma by cancer-associated fibroblasts. CCR5 is highly expressed by mCRC tumor cells, and CCR5 blockade can induce cytotoxic and apoptotic effects in CRC
cancer cells (Weitzenfeld P, Ben-Baruch A.,“The Chemokine System, and its CCR5 and CXCR4 receptors, as Potential Targets for Personalized Therapy in Cancer,” Cancer Lett. 2014 Sep 28;352(l):36-53).
CCR5 antagonism has been shown to impact tumor progression and metastases in several tumor types (eg, gastric, breast, prostate) in nonclinical studies using xenograft models (Velasco-Velazquez, M., et ah,“CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells,” Cancer Res. 2012 Aug l;72(l5):3839-50; Ochoa-Callejero, L., et ah,“Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model,” PLoS One. 2013 Jan;8(l):e53992; Mencarelli, A., et ah,“CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination,” Transl Oncol. 2013 Dec;6(6):784- 93). In these models, the CCR5 antagonist maraviroc has been shown to reduce the
potential for gastric and breast cancer cell dissemination, to prevent the development of gastric tumorigenesis, to reduce prostate cancer bone and brain metastases, and to impede recruitment of immunosuppressive TAMs in triple-negative breast cancer.
These data suggest that CCR5 antagonism might reverse tumor immune suppression causedby immune suppressive cell populations in the tumor microenvironment, such as MDSCs, Tregs, and TAMs. Reversal of this immunosuppression may allow immune checkpoint inhibitors (eg, PDL-l antagonists) to be more effective against CRC, as well os other types of cancer.
SUMMARY OF THE INVENTION
In a first aspect, the invention provides a method of treating a cell proliferation disorder, e.g ., cancer, comprising administering:
(a) vicriviroc, or a pharmaceutically acceptable salt thereof; and
(b) an anti-human PD-l antibody or antigen binding fragment thereof to a human patient in need thereof.
In one embodiment of this method (embodiment no. 1), the cell proliferation disorder is cancer, wherein the cancer is microsatellite stable (MSS) colorectal cancer (CRC), prostate cancer, pancreatic cancer, melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, non-Hodgkin lymphoma, renal cancer, Hodgkin lymphoma,
mesothelioma, microsatellite instability-high cancer, mismatch repair deficient cancer, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, or salivary cancer. Also, in some embodiments above method, the cancer expresses PD-L1, such as cancers having tumors with a PD-L1 tumor
proportion score (TPS) of >1% , >10% or >50%or a PD-L1 combined positive score (CPS) of >1 or >10.. For example, the level of PD-L1 TPS is determined by an FDA-approved test.
In embodiment no. 2 of this method, the cancer is melanoma, NSCLC, head and neck squamous cell cancer (HNSCC), Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, Merkel cell carcinoma, hepatocellular carcinoma or cervical cancer.
In embodiment no. 3 of this method, the cancer is colorectal cancer (CRC). For instance, the colorectal cancer is microsatellite stable (MSS) colorectal cancer (CRC). More specifically, the microsatellite stable colorectal cancer is advanced microsatellite stable colorectal cancer or metastatic microsatellite stable colorectal cancer.
In embodiment no. 4 of this method, the cancer is pancreatic cancer.
In embodiment no. 5 of this method, the cancer is microsatellite stable colorectal cancer.
In embodiment no. 6 of this method, the CCR5 antagonist is vicriviroc maleate.
In embodiment no. 7 of this method, the human patient is administered:
(a) 200 mg, 240 mg, 400 mg, or 480 mg of the anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate; or
(b) 2 mg/kg of an anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate,
wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every two-six weeks and the vicriviroc maleate is administered once daily.
For instance, the human patient is administered 200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and 150 mg of vicriviroc maleate; wherein the anti-human PD- 1 antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily. Additionally, the human patient is administered 200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and 250 mg of vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily.
In embodiment no. 7 of this method, the human patient has been previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan, and have received, been intolerant to, or been ineligible for said therapies.
In a second aspect, the invention provides a kit comprising:
(a) vicriviroc maleate; and
(b) an anti-human PD-l antibody or antigen binding fragment thereof.
In embodiment no. 1 of this kit, the kit further comprises instructions for administering vicriviroc maleate and the anti-human PD-l antibody or antigen binding fragment thereof to a human patient.
In a third aspect, the invention provides a therapeutic combination, comprising:
(a) vicriviroc maleate; and
(b) an anti-human PD-l antibody or antigen binding fragment thereof for treating a cell proliferation disorder, e.g. , cancer, in a human patient.
In certain embodiments of the the first, second, or third aspects, the anti-human PD-l antibody or antigen binding fragment thereof comprises three light chain CDRs of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3 and three heavy chain CDRs of SEQ ID NO:6, SEQ ID NO: 7 and SEQ ID NO:8.
In certain embodiments of the the first, second, or third aspects, the anti-human PD-l antibody or antigen binding fragment thereof comprises a VL region which comprises the amino acid sequence set forth in SEQ ID NO:4, and a VH region which comprises the amino acid sequence set forth in SEQ ID NO:9.
In certain embodiments of the the first, second, or third aspects, the anti-human PD-l antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO: 10.
In certain embodiments of the the first, second, or third aspects, the anti-human PD-l antibody or antigen binding fragment thereof is pembrolizumab.
In certain embodiments of the the first, second, or third aspects, the anti-human PD-l antibody or antigen binding fragment thereof is nivolumab.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 shows CCR5 expression in human tumors.
FIGURE 2 shows the in vitro activity of vicriviroc on MV-4-11 Tumor Cell
Proliferation.
FIGURE 3 shows that vicriviroc enhances antigen-specific IFN-g responses to pembrolizumab oh rhesus monkey T cells.
DETAILED DESCRIPTION OF THE INVENTION
ABBREVIATIONS
pg, ug Microgram
BID One dose twice daily
CDR Complementary determining region
CR Complete regression
Ctrl Control
DFS Disease free survival
DLT Dose limiting toxicity
FFPE Formalin-fixed, paraffin-embedded
FR Framework region
IgG Immunoglobulin G
IgGl Immunoglobulin G subclass 1
IHC Immunohistochemistry or immunohistochemical
IP Intraperitoneal
IT Intratumoral
IV Intravenous
kg Kilogram
mAb Monoclonal antibody
mg Milligram mL Milliliter
mm Millimeter
mm3 Cubic millimeter, 0.001 mL
MPK Milligram per kilogram
MTD Maximum tolerated dose
n Number of subjects in a treatment group
NCI National Cancer Institute
OR Overall response
OS Overall survival
PBS Phosphate-buffered saline, vehicle control for CXCR2 antagonists
PD-l Programmed cell death protein 1
PD-L1 Programmed cell death 1 ligand 1
PD-L2 Programmed cell death 1 ligand 2
PFS Progression free survival
PR Partial response
/>-values Calculated probability
QD One dose per day
RECIST Response Evaluation Criteria in Solid Tumors
SC Subcutaneous
SD Stable disease
SEM Standard error of the mean
TGI Tumor growth inhibition
T/C Median tumor volume of the treated animal/Median tumor volume of the control animal
VH immunoglobulin heavy chain variable region
VK immunoglobulin kappa light chain variable region
VL immunoglobulin light chain variable region
Additional abbreviations may be defined throughout this disclosure.
DEFINITIONS
Certain technical and scientific terms are specifically defined below. Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this disclosure relates.
“About” when used to modify a numerically defined parameter ( e.g ., the dose of an anti -PD- 1 antibody, or antigen binding fragment thereof, or vicriviroc, or a pharmaceutically acceptable salt thereof, or the length of treatment time with a combination therapy described herein) means that the parameter may vary by as much as 10% below or above the stated numerical value for that parameter; where appropriate, the stated parameter may be rounded to the nearest whole number. For example, a dose of about 5 mg/kg may vary between 4.5 mg/kg and 5.5 mg/kg.
As used herein, including the appended claims, the singular forms of words such as“a,”“an,” and“the,” include their corresponding plural references unless the context clearly dictates otherwise.
The terms“administration of’ and or“administering” a compound should be understood to include providing a compound described herein, or a pharmaceutically acceptable salt thereof, and compositions of the foregoing to a subject.
As used herein, the term“antibody” refers to any form of immunoglobulin molecule that exhibits the desired biological or binding activity. Thus, it is used in the broadest sense and specifically covers, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized, fully human antibodies, and chimeric antibodies.“Parental antibodies” are antibodies obtained by exposure of an immune system to an antigen prior to modification of the antibodies for an intended use, such as humanization of an antibody for use as a human
therapeutic. As used herein, the term“antibody” encompasses not only intact polyclonal or monoclonal antibodies, but also, unless otherwise specified, any antigen binding portion thereof that competes with the intact antibody for specific binding, fusion proteins comprising an antigen binding portion, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site.
In general, the basic antibody structural unit comprises a tetramer. Each tetramer includes two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The variable regions of each light/heavy chain pair form the antibody binding site. Thus, in general, an intact antibody has two binding sites. The carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function. Typically, human light chains are classified as kappa and lambda light chains. Furthermore, human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See generally,
Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989).
As used herein, unless otherwise indicated,“antibody fragment” or“antigen binding fragment” refers to a fragment of an antibody that retains the ability to bind specifically to the antigen, e.g ., fragments that retain one or more CDR regions. An antibody that “specifically binds to” PD-l or PD-L1 is an antibody that exhibits preferential binding to PD-l or PD-L1 (as appropriate) as compared to other proteins, but this specificity does not require absolute binding specificity. An antibody is considered“specific” for its intended target if its binding is determinative of the presence of the target protein in a sample, e.g. , without producing undesired results such as false positives. Antibodies, or binding fragments thereof, will bind to the target protein with an affinity that is at least two fold greater, preferably at least ten times greater, more preferably at least 20-times greater, and most preferably at least lOO-times greater than the affinity with non-target proteins.
Antigen binding portions include, for example, Fab, Fab’, F(ab’)2, Fd, Fv, fragments including complementarity determining regions (CDRs), and single chain variable fragment antibodies (scFv), and polypeptides that contain at least a portion of an
immunoglobulin that is sufficient to confer specific antigen binding to the PD-l or PD-L1. An antibody includes an antibody of any class, such as IgG, IgA, or IgM (or sub-class thereof), and
the antibody need not be of any particular class. Depending on the antibody amino acid sequence of the constant region of its heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g, IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2. The heavy-chain constant regions that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
As used herein, the terms“at least one” item or“one or more” item each include a single item selected from the list as well as mixtures of two or more items selected from the list.
As used herein, the term“immune response” relates to any one or more of the following: specific immune response, non-specific immune response, both specific and non specific response, innate response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell-proliferation, immune cell differentiation, and cytokine expression.
The term“pharmaceutically acceptable carrier” refers to any inactive substance that is suitable for use in a formulation for the delivery of a therapeutic agent. A carrier may be an antiadherent, binder, coating, disintegrant, filler or diluent, preservative (such as antioxidant, antibacterial, or antifungal agent), sweetener, absorption delaying agent, wetting agent, emulsifying agent, buffer, and the like. Examples of suitable pharmaceutically acceptable carriers include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), dextrose, vegetable oils (such as olive oil), saline, buffer, buffered saline, and isotonic agents such as sugars, polyalcohols, sorbitol, and sodium chloride.
The term“subject” (alternatively“patient”) as used herein refers to a mammal that has been the object of treatment, observation, or experiment. The mammal may be male or female. The mammal may be one or more selected from the group consisting of humans, bovine (e.g, cows), porcine (e.g, pigs), ovine (e.g, sheep), capra (e.g, goats), equine (e.g, horses), canine (e.g, domestic dogs), feline (e.g, house cats), Lagomorpha (rabbits), rodents (e.g, rats or mice), Procyon lotor (e.g, raccoons). In particular embodiments, the subject is human.
The term“subject in need thereof’ as used herein refers to a subject diagnosed with, or suspected of having, a cell-proliferation disorder, such as a cancer, as defined herein.
As used herein, the terms“treatment” and“treating” refer to all processes in which there may be a slowing, interrupting, arresting, controlling, or stopping of the progression
of a disease or disorder described herein. The terms do not necessarily indicate a total elimination of all disease or disorder symptoms.
“Variable regions” or“V region” or“V chain” as used herein means the segment of IgG chains which is variable in sequence between different antibodies. A“variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. Typically, the variable regions of both the heavy and light chains comprise three hypervariable regions, also called complementarity determining regions (CDRs), which are located within relatively conserved framework regions (FR). The CDRs are usually aligned by the framework regions, enabling binding to a specific epitope. In general, from N-terminal to C-terminal, both light and heavy chains variable domains comprise FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The assignment of amino acids to each domain is, generally, in accordance with the definitions of Sequences of Proteins of Immunological Interest, Rabat, et al:, National Institutes of Health, Bethesda, Md.; 5th ed.; NIH Publ. No. 91-3242 (1991); Rabat (1978) Adv. Prot. Chem. 32: 1-75; Rabat, et al. , (1977) J. Biol. Chem. 252:6609-6616; Chothia, et al. , (1987) J Mol. Biol. 196:901-917 or Chothia, et al. , (1989) Nature 342:878-883.
“Chimeric antibody” refers to an antibody in which a portion of the heavy and/or light chain contains sequences derived from a particular species ( e.g ., human) or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is derived from another species (e.g., mouse) or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
“Human antibody” refers to an antibody that comprises human immunoglobulin protein sequences or derivatives thereof. A human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell. Similarly,“mouse antibody” or“rat antibody” refer to an antibody that comprises only mouse or rat immunoglobulin sequences or derivatives thereof, respectively.
“Humanized antibody” refers to forms of antibodies that contain sequences from non-human (e.g, murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human
immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
The prefix“hum”,“hu” or“h” may be added to antibody clone designations when necessary to distinguish humanized antibodies from parental rodent antibodies. The humanized forms of rodent antibodies will generally comprise the same CDR sequences of the parental rodent antibodies, although certain amino acid substitutions may be included to increase affinity, increase stability of the humanized antibody, or for other reasons.
“Biotherapeutic agent” means a biological molecule, such as an antibody or fusion protein, that blocks ligand/receptor signaling in any biological pathway that supports tumor maintenance and/or growth or suppresses the anti-tumor immune response.
“Chemotherapeutic agent” refers to a chemical or biological substance that can cause death of cancer cells, or interfere with growth, division, repair, and/or function of cancer cells. Examples of chemotherapeutic agents include those that are disclosed in WO2006/129163, and US20060153808. Classes of chemotherapeutic agents include, but are not limited to:
alkylating agents, antimetabolites, kinase inhibitors, spindle poison, plant alkaloids,
cytoxic/antitumor antibiotics, topisomerase inhibitors, photosensitizers, anti-estrogens and selective estrogen receptor modulators (SERMs), anti-progesterones, estrogen receptor down- regulators (ERDs), estrogen receptor antagonists, leutinizing hormone-releasing hormone agonists, anti-androgens, aromatase inhibitors, EGFR inhibitors, VEGF inhibitors, and anti-sense oligonucleotides that inhibit expression of genes implicated in abnormal cell-proliferation or tumor growth. Chemotherapeutic agents useful in the treatment methods of the present disclosure include cytostatic and/or cytotoxic agents.
The therapeutic agents and compositions provided by the present disclosure can be administered via any suitable enteral route or parenteral route of administration. The term “enteral route” of administration refers to the administration via any part of the gastrointestinal tract. Examples of enteral routes include oral, mucosal, buccal, and rectal route, or intragastric route.“Parenteral route” of administration refers to a route of administration other than enteral route. Examples of parenteral routes of administration include intravenous, intramuscular, intradermal, intraperitoneal, intratumor, intravesical, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, transtracheal, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal, subcutaneous, or topical administration. The therapeutic agents and compositions of the disclosure can be administered using any suitable method, such as by oral ingestion, nasogastric tube, gastrostomy tube, injection, infusion, implantable infusion pump, and osmotic pump. The suitable route and method of administration may vary depending on a number of factors such as the specific therapeutic agent being used, the rate of absorption desired, specific formulation or dosage form used, type or severity of the disorder being treated,
the specific site of action, and conditions of the patient, and can be readily selected by a person skilled in the art.
The term“simultaneous administration” as used herein in relation to the administration of medicaments refers to the administration of medicaments such that the individual medicaments are present within a subject at the same time. In addition to the concomitant administration of medicaments (via the same or alternative routes), simultaneous administration may include the administration of the medicaments (via the same or an alternative route) at different times.
“Chothia” as used herein means an antibody numbering system described in Al- Lazikani et al. , JMB 273:927-948 (1997).
“Conservatively modified variants” or“conservative substitution” refers to substitutions of amino acids in a protein with other amino acids having similar characteristics ( e.g ., charge, side-chain size, hydrophobicity/hydrophilicity, backbone conformation and rigidity, etc.), such that the changes can frequently be made without altering the biological activity or other desired property of the protein, such as antigen affinity and/or specificity.
Those of skill in this art recognize that, in general, single amino acid substitutions in non- essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin/Cummings Pub. Co., p. 224 (4th Ed.)). In addition, substitutions of structurally or functionally similar amino acids are less likely to disrupt biological activity. Exemplary conservative substitutions are set forth in Table 1 below.
Table 1. Exemplary Conservative Amino Acid Substitutions
“Consists essentially of,” and variations such as“consist essentially of’ or “consisting essentially of,” as used throughout the specification and claims, indicate the inclusion of any recited elements or group of elements, and the optional inclusion of other elements, of similar or different nature than the recited elements, that do not materially change the basic or novel properties of the specified dosage regimen, method, or composition.
“Diagnostic anti-PD-L monoclonal antibody” means a mAh that specifically binds to the mature form of the designated PD-L (PD-L1 or PD-L2) expressed on the surface of certain mammalian cells. A mature PD-L lacks the presecretory leader sequence, also referred to as leader peptide. The terms“PD-L” and“mature PD-L” are used interchangeably herein, and shall be understood to mean the same molecule unless otherwise indicated or readily apparent from the context.
As used herein, a diagnostic anti-human PD-L1 mAh or an anti-hPD-Ll mAh refers to a monoclonal antibody that specifically binds to mature human PD-L1. A mature human PD-L1 molecule consists of amino acids 19-290 set forth in SEQ ID NO 21 (Table 3).
Specific examples of diagnostic anti-human PD-L1 mAbs useful as diagnostic mAbs for IHC detection of PD-L1 expression in FFPE tumor tissue sections are antibodies 20C3 and 22C3, which are described in PCT International Patent Application Publication No.
W02014/100079. Another anti-human PD-L1 mAh that has been reported to be useful for IHC detection of PD-L1 expression in FFPE tissue sections (Chen, B.J. et al ., Clin Cancer Res 19: 3462-3473 (2013)) is a rabbit anti-human PD-L1 mAh publicly available from Sino Biological, Inc. (Beijing, P.R. China; Catalog number 10084-R015).
“CPS” or“combined positive score” refers to an algorithm for determining a PD- Ll expression score from a tumor sample of a patient. The CPS is useful in selecting patients for treatment with particular treatment regimens including methods of treatment comprising administration of an anti-PD-l antibody in which expression of PD-L1 is associated with a higher response rate in a particular patient population relative to same patient population that does not express PD-L1. The CPS is determined by determining the number of viable PD-L1 positive tumor cells, the number of viable PD-L1 negative tumor cells, and the number of viable PD-L1 positive mononuclear inflammatory cells (MIC) in a tumor tissue from a patient having a tumor and calculating the CPS using the following formula:
(# PD-L1 positive tumor cells) + (# PD-L1 positive MIC) x 100%
(# PD-L1 positive tumor cells) + (PD-L1 negative tumor cells).
“TPS” or“tumor proportion score” is the percentage of tumor cells expressing PD-L1 on the cell membrane. TPS typically includes the percentage of neoplastic cells expressing PD-L1 at any intensity (weak, moderate, or strong), which can be determining using an immunohistochemical assay using a diagnostic anti-human PD-L1 mAb, e.g. antibody 20C3 and antibody 22C3, described, supra. Cells are considered to express PD-L1 if membrane staining is present, including cells with partial membrane staining.
“Homology” refers to sequence similarity between two polypeptide sequences when they are optimally aligned. When a position in both of the two compared sequences is occupied by the same amino acid monomer subunit, e.g., if a position in a light chain CDR of two different Abs is occupied by alanine, then the two Abs are homologous at that position. The percent of homology is the number of homologous positions shared by the two sequences divided by the total number of positions compared c 100. For example, if 8 of 10 of the positions in two sequences are matched when the sequences are optimally aligned then the two sequences are 80% homologous. Generally, the comparison is made when two sequences are aligned to give maximum percent homology. For example, the comparison can be performed by a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences.
The following references relate to BLAST algorithms often used for sequence analysis: BLAST ALGORITHMS: Altschul, S.F., et al, (1990) J. Mol. Biol. 215:403-410; Gish, W., et al., (1993) Nature Genet. 3:266-272; Madden, T.L., et al, (1996) Meth. Enzymol.
266: 131-141; Altschul, S.F., et al, (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et al,
(1997) Genome Res. 7:649-656; Wootton, J.C., et al, (1993) Comput. Chem. 17: 149-163;
Hancock, J.M. et al. , (1994) Comput. Appl. Biosci. 10:67-70; ALIGNMENT SCORING
SYSTEMS: Dayhoff, M.O., et al.,“A model of evolutionary change in proteins.” in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3. M.O. Dayhoff (ed.), pp. 345-352, Natl. Biomed. Res. Found., Washington, DC; Schwartz, R.M., et al. ,“Matrices for detecting distant relationships.” in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3.” M.O.
Dayhoff (ed.), pp. 353-358, Natl. Biomed. Res. Found., Washington, DC; Altschul, S.F., (1991)
J. Mol. Biol. 219:555-565; States, D.J., et al., (1991) Methods 3:66-70; Henikoff, S., et al.,
(1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919; Altschul, S.F., et al., (1993) J. Mol. Evol. 36:290-300; ALIGNMENT STATISTICS: Karlin, S., et al., (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268; Karlin, S., et al., (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877; Dembo, A., et al, (1994) Ann. Prob. 22:2022-2039; and Altschul, S.F.“Evaluating the statistical significance of multiple distinct local alignments.” in Theoretical and Computational Methods in Genome Research (S. Suhai, ed.), (1997) pp. 1-14, Plenum, New York.
The term“isolated” as used in reference to an antibody or fragment thereof refers to the purification status and, in such context, means the named molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term“isolated” is not intended to refer to a complete absence of such material or to an absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with experimental or therapeutic use of the binding compound as described herein.
“Kabat” as used herein means an immunoglobulin alignment and numbering system pioneered by Elvin A. Kabat ((1991) Sequences of Proteins of Immunological Interest,
5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.).
“Monoclonal antibody” or“mAh” or“Mab”, as used herein, refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains, particularly their CDRs, which are often specific for different epitopes. The modifier“monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA
methods (see, e.g, U.S. Pat. No. 4,816,567). The“monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson el al. (1991) Nature 352: 624-628 and Marks et al. (1991) J Mol. Biol. 222: 581-597, for example. See also Presta (2005) J. Allergy Clin. Immunol. 116:731.
“RECIST 1.1 Response Criteria” as used herein means the definitions set forth in Eisenhauer, E.A. et al., Eur. J. Cancer 45:228-247 (2009) for target lesions or nontarget lesions, as appropriate based on the context in which response is being measured.
“Sustained response” means a sustained therapeutic effect after cessation of treatment as described herein. In some embodiments, the sustained response has a duration that is at least the same as the treatment duration, or at least 1.5, 2.0, 2.5 or 3 times longer than the treatment duration.
“Tissue Section” refers to a single part or piece of a tissue, e.g. , a thin slice of tissue cut from a sample of a normal tissue or of a tumor.
“Treat” or“treating” a cell-proliferation disorder as used herein means to administer a combination therapy of an anti-human PD-l antibody (or antigen binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, to a subject having a cell- proliferation disorder, such as cancer, or diagnosed with a cell-proliferation disorder, such as cancer, to achieve at least one positive therapeutic effect, such as for example, reduced number of cancer cells, reduced tumor size, reduced rate of cancer cell infiltration into peripheral organs, or reduced rate of tumor metastasis or tumor growth. Such“treatment” may result in a slowing, interrupting, arresting, controlling, or stopping of the progression of a cell-proliferation disorder as described herein but does not necessarily indicate a total elimination of the cell-proliferation disorder or the symptoms of the cell-proliferation disorder. Positive therapeutic effects in cancer can be measured in a number of ways (See, W. A. Weber, J. Nucl. Med. 50: lS-l0S (2009)). For example, with respect to tumor growth inhibition, according to NCI standards, a T/C £ 42% is the minimum level of anti -tumor activity. A T/C < 10% is considered a high anti -tumor activity level, with T/C (%) = Median tumor volume of the treated/Median tumor volume of the control c 100. In some embodiments, the treatment achieved by a combination therapy of the disclosure is any of PR, CR, OR, PFS, DFS, and OS. PFS, also referred to as“Time to Tumor Progression” indicates the length of time during and after treatment that the cancer does not grow, and includes the amount of time patients have experienced a CR or PR, as well as the amount of time patients have experienced SD. DFS refers to the length of time during and after treatment that the patient remains free of disease. OS refers to a prolongation in life expectancy as compared to naive or untreated individuals or patients. In some embodiments, response to a combination
therapy of the disclosure is any of PR, CR, PFS, DFS, or OR that is assessed using RECIST 1.1 response criteria. The treatment regimen for a combination therapy of the disclosure that is effective to treat a cancer patient may vary according to factors such as the disease state, age, and weight of the patient, and the ability of the therapy to elicit an anti-cancer response in the subject. While an embodiment of any of the aspects of the disclosure may not be effective in achieving a positive therapeutic effect in every subject, it should do so in a statistically significant number of subjects as determined by any statistical test known in the art such as the Student’ s t-test, the chi2-test, the U-test according to Mann and Whitney, the Kruskal -Wallis test (H-test), Jonckheere-Terpstra-test and the Wilcoxon-test.
As used herein, the terms“combination therapy” and“therapeutic combination” refer to treatments in which at least one anti -human PD-l antibody (or antigen-binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, and optionally additional therapeutic agents, each are administered to a patient in a coordinated manner, over an overlapping period of time. The period of treatment with the at least one anti -human PD-l antibody (or antigen-binding fragment thereof) (the“anti -PD-l treatment”) is the period of time that a patient undergoes treatment with the anti-human PD-l antibody (or antigen-binding fragment thereof); that is, the period of time from the initial dosing with the anti-human PD-l antibody (or antigen-binding fragment thereof) through the final day of a treatment cycle.
Similarly, the period of treatment with vicriviroc, or a pharmaceutically acceptable salt thereof, (the“vicriviroc treatment”) is the period of time that a patient undergoes treatment with vicriviroc, or a pharmaceutically acceptable salt thereof; that is, the period of time from the initial dosing with vicriviroc, or a pharmaceutically acceptable salt thereof, through the final day of a treatment cycle. In the methods and therapeutic combinations described herein, the anti-PD- 1 treatment overlaps by at least one day the vicriviroc treatment. In certain embodiments, the anti -PD-l treatment and the vicriviroc treatment are coextensive. In embodiments, the anti -PD-l treatment begins prior to the vicriviroc treatment. In embodiments, the vicriviroc treatment begins prior to the anti-PD-l treatment. In embodiments, the anti-PD-l treatment is terminated prior to termination of vicriviroc treatment. In embodiments, the vicriviroc treatment is terminated prior to termination of the anti-PD-l treatment.
The terms“treatment regimen”,“dosing protocol”, and“dosing regimen” are used interchangeably to refer to the dose and timing of administration of each therapeutic agent in a combination therapy of the disclosure.
“Tumor” as it applies to a subject diagnosed with, or suspected of having, a cancer refers to a malignant or potentially malignant neoplasm or tissue mass of any size, and
includes primary tumors and secondary neoplasms. A solid tumor is an abnormal growth or mass of tissue that usually does not contain cysts or liquid areas. Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors (National Cancer Institute, Dictionary of Cancer Terms).
“Advanced solid tumor malignancy” and“advanced solid tumor” are used interchangeably to refer to a tumor for which curative resection is not possible. Advanced solid tumors include, but are not limited to, metastatic tumors in bone, brain, breast, liver, lungs, lymph node, pancreas, prostate, and soft tissue (sarcoma).
“Tumor burden” also referred to as“tumor load”, refers to the total amount of tumor material distributed throughout the body. Tumor burden refers to the total number of cancer cells or the total size of tumor(s), throughout the body, including lymph nodes and bone narrow. Tumor burden can be determined by a variety of methods known in the art, such as, e.g ., by measuring the dimensions of tumor(s) upon removal from the subject, e.g. , using calipers, or while in the body using imaging techniques, e.g. , ultrasound, bone scan, computed tomography (CT) or magnetic resonance imaging (MRI) scans.
The term“tumor size” refers to the total size of the tumor which can be measured as the length and width of a tumor. Tumor size may be determined by a variety of methods known in the art, such as, e.g. , by measuring the dimensions of tumor(s) upon removal from the subject, e.g. , using calipers, or while in the body using imaging techniques, e.g. , bone scan, ultrasound, CT or MRI scans.
It is understood that wherever embodiments are described herein with the language“comprising,” otherwise analogous embodiments described in terms of“consisting of’ and/or“consisting essentially of’ are also provided.
Unless expressly stated to the contrary, all ranges cited herein are inclusive; i.e., the range includes the values for the upper and lower limits of the range as well as all values in between. As an example, temperature ranges, percentages, ranges of equivalents, and the like described herein include the upper and lower limits of the range and any value in the continuum there between. Numerical values provided herein, and the use of the term“about”, may include variations of ± 1%, ± 2%, ±3%, ± 4%, ± 5%, ± 10%, ± 15%, and ± 20% and their numerical equivalents. All ranges also are intended to include all included sub-ranges, although not necessarily explicitly set forth. For example, a range of 3 to 7 days is intended to include 3, 4, 5, 6, and 7 days. In addition, the term "or," as used herein, denotes alternatives that may, where
appropriate, be combined; that is, the term "or" includes each listed alternative separately as well as their combination.
Where aspects or embodiments of the disclosure are described in terms of a Markush group or other grouping of alternatives, the present disclosure encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, but also the main group absent one or more of the group members. The present disclosure also envisages the explicit exclusion of one or more of any of the group members in the claims.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure relates. In case of conflict, the present specification, including definitions, will control. Throughout this specification and claims, the word“comprise,” or variations such as “comprises” or“comprising” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Any example(s) following the term“e. .” or“for example” is not meant to be exhaustive or limiting.
Exemplary methods and materials are described herein, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. The materials, methods, and examples are illustrative only and not intended to be limiting.
The present disclosure relates to methods of treating a cell-proliferation disorder as defined herein, wherein the method comprises administering to a human patient in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody, or antigen binding fragment thereof; and (b) vicriviroc, or a pharmaceutically acceptable salt thereof.
The present disclosure also relates to a therapeutic combination, wherein the therapeutic combination comprises (a) an anti-human PD-l antibody, or antigen-binding fragment thereof; and (b) vicriviroc, or a pharmaceutically acceptable salt thereof.
In some embodiments of the methods and the therapeutic combination, the anti human PD-l antibody is pembrolizumab.
Anti-PD-l Antibodies and Antigen-Binding Fragments Thereof
The invention provides therapeutic combinations comprising antibodies or antigen binding fragments thereof, which specifically bind to human PD-l ( e.g ., a human or
humanized anti -PD- 1 antibody) and vicriviroc, or a pharmaceutically acceptable salt thereo, as well as methods for using the therapeutic combinations of the invention. Any anti-human PD-l antibody or antigen binding fragment thereof can be used in the therapeutic combinations and methods of the invention. In particular embodiments, the anti-human PD-l antibody is selected from pembrolizumab and nivolumab. In specific embodiments, the anti-human PD-l antibody is pembrolizumab. In alternative embodiments, the anti-human PD-l antibody is nivolumab.
Table 2 provides amino acid sequences for exemplary anti-human PD-l antibodies
pembrolizumab and nivolumab
In some embodiments, an anti-human PD-l antibody or antigen binding fragment thereof for use in the therapeutic combinations and methods of the invention comprises three light chain CDRs of CDRL1, CDRL2 and CDRL3 and/or three heavy chain CDRs of CDRH1, CDRH2 and CDRH3.
In one embodiment of the invention, CDRL1 is SEQ ID NO: 1 or a variant of SEQ ID NO: 1, CDRL2 is SEQ ID NO:2 or a variant of SEQ ID NO:2, and CDRL3 is SEQ ID NO:3 or a variant of SEQ ID NO:3.
In one embodiment, CDRH1 is SEQ ID NO:6 or a variant of SEQ ID NO:6, CDRH2 is SEQ ID NO: 7 or a variant of SEQ ID NO:7, and CDRH3 is SEQ ID NO:8 or a variant of SEQ ID NO:8.
In one embodiment, the three light chain CDRs are SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO: 3 and the three heavy chain CDRs are SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO:8.
In an alternative embodiment of the invention, CDRL1 is SEQ ID NO: 11 or a variant of SEQ ID NO: 11, CDRL2 is SEQ ID NO: 12 or a variant of SEQ ID NO: 12, and CDRL3 is SEQ ID NO: 13 or a variant of SEQ ID NO: 13.
In one embodiment, CDRH1 is SEQ ID NO: 16 or a variant of SEQ ID NO: 16, CDRH2 is SEQ ID NO: 17 or a variant of SEQ ID NO: 17, and CDRH3 is SEQ ID NO: 18 or a variant of SEQ ID NO: 18.
In an alternative embodiment, the three light chain CDRs are SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13 and the three heavy chain CDRs are SEQ ID
NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18.
Some antibody and antigen binding fragments used in the therapeutic combinations and methods of the invention comprise a light chain variable region and a heavy chain variable region. In some embodiments, the light chain variable region comprises SEQ ID NO:4 or a variant of SEQ ID NO:4, and the heavy chain variable region comprises SEQ ID NO:9
or a variant of SEQ ID NO:9. In further embodiments, the light chain variable region comprises SEQ ID NO: 14 or a variant of SEQ ID NO: 14, and the heavy chain variable region comprises SEQ ID NO: 19 or a variant of SEQ ID NO: 19. In such embodiments, a variant light chain or heavy chain variable region sequence is identical to the reference sequence except having one, two, three, four or five amino acid substitutions. In some embodiments, the substitutions are in the framework region (i.e., outside of the CDRs). In some embodiments, one, two, three, four or five of the amino acid substitutions are conservative substitutions.
In one embodiment of the therapeutic combinations and methods of the invention, the antibody or antigen binding fragment comprises a light chain variable region comprising or consisting of SEQ ID NO:4 and a heavy chain variable region comprising or consisting SEQ ID NO:9. In a further embodiment, the antibody or antigen binding fragment comprises a light chain variable region comprising or consisting of SEQ ID NO: 14 and a heavy chain variable region comprising or consisting of SEQ ID NO: 19.
In another embodiment, the therapeutic combinations and methods of the invention comprise an antibody or antigen binding protein that has a VL domain and/or a VH domain with at least 98%, 95%, 90%, 85%, 80%, 75% or 50% sequence homology to one of the VL domains or VH domains described above, and exhibits specific binding to PD-l . In another embodiment, the antibody or antigen binding protein of the therapeutic combinations and methods of the invention comprises VL and VH domains having up to 1, 2, 3, 4, or 5 or more amino acid substitutions, and exhibits specific binding to PD-l. In specific embodiments, the amino acid substitutions are conservative substitutions.
In any of the embodiments above, the therapeutic combinations and methods may use a full-length anti -PD-l antibody or an antigen binding fragment thereof that specifically binds human PD-l. In certain embodiments, a full-length anti-human PD-l antibody selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE is used. Preferably, the antibody is an IgG antibody. Any isotype of IgG can be used, including IgGi, IgG2, IgG3, and IgG4. Different constant domains may be appended to the VL and VH regions provided herein. For example, if a particular intended use of an antibody (or fragment) of the present invention were to call for altered effector functions, a heavy chain constant domain other than IgGl may be used. Although IgGl antibodies provide for long half-life and for effector functions, such as complement activation and antibody-dependent cellular cytotoxicity, such activities may not be desirable for all uses of the antibody. In such instances an IgG4 constant domain, for example, may be used.
In embodiments of the invention, the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:5 or a variant of SEQ ID NO:5, and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 10, or a variant of SEQ ID NO: 10. In alternative embodiments, the therapeutic
combinations and methods use an anti -human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 15, or a variant of SEQ ID NO: 15, and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:20, or a variant of SEQ ID NO: 15. In embodiments of the invention, the variant of SEQ ID NO:5, 10, 15 or 20 has up to 1, 2, 3, 4, 5, 6, 7, 8 or 9 conservative amino acid substitutions. In further embodiments, the variant of SEQ ID NO:5, 10, 15, or 20 has a C-terminal deletion/truncation of 1, 2, 3, 4, or 5 amino acids.
In one embodiment, the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 10. In an alternative embodiment, the therapeutic combinations and methods use an anti-human PD-l antibody comprising a light chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO: 15 and a heavy chain comprising or consisting of a sequence of amino acid residues as set forth in SEQ ID NO:20.
In some therapeutic combinations and methods of the invention, the anti-human PD-l antibody is pembrolizumab or a pembrolizumab biosimilar. In some therapeutic combinations and methods of the invention, the anti-human PD-l antibody is nivolumab or a nivolumab biosimilar.
Ordinarily, amino acid sequence variants of the anti -PD-l antibodies and antigen binding fragments used in the invention will have an amino acid sequence having at least 75% amino acid sequence identity with the amino acid sequence of a reference antibody or antigen binding fragment ( e.g ., heavy chain, light chain, VH, VL, or humanized sequence), more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95, 98, or 99%. Identity or homology with respect to a sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the anti -PD-l residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal, or internal
extensions, deletions, or insertions into the antibody sequence shall be construed as affecting sequence identity or homology.
Sequence identity refers to the degree to which the amino acids of two
polypeptides are the same at equivalent positions when the two sequences are optimally aligned. Sequence identity can be determined using a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences. The following references relate to BLAST algorithms often used for sequence analysis: BLAST ALGORITHMS: Altschul, S.F., et al ., (1990) J. Mol. Biol. 215:403-410; Gish, W., et al. , (1993) Nature Genet. 3:266-272; Madden, T.L., et al, (1996) Meth. Enzymol. 266: 131-141; Altschul, S.F., et al, (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et al, (1997) Genome Res. 7:649-656; Wootton, J.C., et al, (1993) Comput. Chem. 17: 149-163; Hancock, J.M. et al, (1994) Comput. Appl. Biosci. 10:67- 70; ALIGNMENT SCORING SYSTEMS: Dayhoff, M.O., et al. , "A model of evolutionary change in proteins." in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3. M.O. Dayhoff (ed.), pp. 345-352, Natl. Biomed. Res. Found., Washington, DC; Schwartz, R.M., et al. , "Matrices for detecting distant relationships." in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3." M.O. Dayhoff (ed.), pp. 353-358, Natl. Biomed. Res. Found., Washington, DC; Altschul, S.F., (1991) J. Mol. Biol. 219:555-565; States, D.J., et al, (1991) Methods 3:66-70; Henikoff, S., et al, (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919; Altschul, S.F., et al, (1993) J. Mol. Evol. 36:290-300; ALIGNMENT STATISTICS: Karlin, S., et al. , (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268; Karlin, S., et al. , (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877; Dembo, A., et al. , (1994) Ann. Prob. 22:2022-2039; and Altschul, S.F.
"Evaluating the statistical significance of multiple distinct local alignments." in Theoretical and Computational Methods in Genome Research (S. Suhai, ed.), (1997) pp. 1-14, Plenum, New York.
Table 2. Exemplary PD-l Antibody Sequences
Table 3. Human PD-L1 Sequence (amino acid residues 19-290)
“PD-L1” expression expression as used herein means any detectable level of expression of the designated PD-L protein on the cell surface or of the designated PD-L mRNA within a cell or tissue. PD-L protein expression may be detected with a diagnostic PD-L antibody in an IHC assay of a tumor tissue section or by flow cytometry. Alternatively, PD-L protein expression by tumor cells may be detected by PET imaging, using a binding agent ( e.g ., antibody fragment, affibody, and the like) that specifically binds to PD-L1. Techniques for detecting and measuring PD-L mRNA expression include RT-PCR and realtime quantitative RT- PCR.
Several approaches have been described for quantifying PD-L1 protein expression in IHC assays of tumor tissue sections. See , e.g., Thompson, R. H., et al., PNAS 101 (49);
17174-17179 (2004); Thompson, R. H. et al, Cancer Res. 66:3381-3385 (2006); Gadiot, L, et al., Cancer 117:2192-2201 (2011); Taube, J. M. et al., Sci TranslMed 4, l27ra37 (2012); and Toplian, S. L. et al., New Eng. JMed. 366 (26): 2443-2454 (2012).
One approach employs a simple binary end-point of positive or negative for PD- Ll expression, with a positive result defined in terms of the percentage of tumor cells that exhibit
histologic evidence of cell-surface membrane staining. A tumor tissue section is counted as positive for PD-L1 expression is at least 1%, and preferably 5% of total tumor cells.
In another approach, PD-L1 expression in the tumor tissue section is quantified in the tumor cells as well as in infiltrating immune cells, which predominantly comprise lymphocytes. The percentage of tumor cells and infiltrating immune cells that exhibit membrane staining are separately quantified as < 5%, 5 to 9%, and then in 10% increments up to 100%.
For tumor cells, PD-L1 expression is counted as negative if the score is < 5% score and positive if the score is > 5%. PD-L1 expression in the immune infiltrate is reported as a semi-quantitative measurement called the adjusted inflammation score (AIS), which is determined by multiplying the percent of membrane staining cells by the intensity of the infiltrate, which is graded as none (0), mild (score of 1, rare lymphocytes), moderate (score of 2, focal infiltration of tumor by lymphohistiocytic aggregates), or severe (score of 3, diffuse infiltration). A tumor tissue section is counted as positive for PD-L1 expression by immune infiltrates if the AIS is > 5.
The level of PD-L1 mRNA expression may be compared to the mRNA expression levels of one or more reference genes that are frequently used in quantitative
RT-PCR, such as ubiquitin C.
In some embodiments, a level of PD-L1 expression (protein and/or mRNA) by malignant cells and/or by infiltrating immune cells within a tumor is determined to be “overexpressed” or“elevated” based on comparison with the level of PD-L1 expression (protein and/or mRNA) by an appropriate control. For example, a control PD-L1 protein or mRNA expression level may be the level quantified in nonmalignant cells of the same type or in a section from a matched normal tissue. In some embodiments, PD-L1 expression in a tumor sample is determined to be elevated if PD-L1 protein (and/or PD-L1 mRNA) in the sample is at least 10%, 20%, 30% , or 50% greater than in the control.
CCR5 ANTAGONIST
A CCR5 antagonist useful in the methods and therapeutic compositions of the invention is vicriviroc, or a pharmaceutically acceptable salt thereof. Vicriviroc maleate (also known as MK-7690, formerly SCH 417690 and SCH-D) is an orally available small molecule cysteine-cysteine motif chemokine receptor 5 (CCR5) antagonist. The chemical name of vicriviroc is l-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-l(R)-[4- (trifluoromethyl)phenyl]ethyl]-3(S)-methyl-l-piperazinyl]-4-methyl-piperidine, 2(Z)- butenedioate(l : 1) and it has the following structure:
Vicriviroc and it’s activity as a CCR5 antagonist is described in Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W.,“Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity Against Human Immunodeficiency Virus Typel” Antimicrob Agents Chemother. 2005 Dec;49(l2):49l 1-9.
Salts
As indicated above, the compounds of the present invention can be employed in the form of pharmaceutically acceptable salts. Those skilled in the art will recognize those instances in which the compounds of the invention may form salts. Examples of such compounds are described herein by reference to possible salts. Such reference is for illustration only. Pharmaceutically acceptable salts can be used with compounds for treating patients. Non- pharmaceutical salts may, however, be useful in the preparation of intermediate compounds.
The term“pharmaceutically acceptable salt” refers to a salt (including an inner salt such as a zwitterion) that possesses effectiveness similar to the parent compound and that is not biologically or otherwise undesirable ( e.g ., is neither toxic nor otherwise deleterious to the recipient thereof). Thus, an embodiment of the invention provides pharmaceutically acceptable salts of the compounds of the invention. The term“salt(s)”, as employed herein, denotes any of the following: acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. Salts of compounds of the invention may be formed by methods known to those of ordinary skill in the art, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates,
benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates (“mesylates”), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. Suitable salts include acid addition salts that may, for example, be formed by mixing a
solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Additionally, acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al , Camille G. (eds.), Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley - VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould,
International J. of Pharmaceutics (1986) T3 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug
Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, /-butyl amine, choline, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g, dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g, benzyl and phenethyl bromides), and others. Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g, sodium or potassium salts), alkaline earth metal salts (e.g, calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
In addition, when a compound of the invention contains both a basic moiety, such as, but not limited to an aliphatic primary, secondary, tertiary or cyclic amine, an aromatic or heteroaryl amine, pyridine or imidazole, and an acidic moiety, such as, but not limited to tetrazole or carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the terms“salt(s)” as used herein. It is understood that certain compounds of the invention may exist in zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the invention.
Administration
The present disclosure relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof.
Anti-PD-l antibodies, or antigen-binding fragments thereof, may be provided by continuous infusion, or by doses administered, e.g., weekly, bi-weekly, tri -weekly, monthly, bimonthly, every six weeks, etc. Doses may be provided, e.g , intravenously, subcutaneously, topically, orally, nasally, intramuscularly, or intratumorally. In certain embodiments, the doses are provided intravenously or subcutaneously. A total dose for a treatment interval is generally at least 0.05 pg/kg body weight, more generally at least 0.2 pg/kg, 0.5 pg/kg, 1 pg/kg, 10 pg/kg, 100 pg/kg, 0.25 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, 5.0 mg/kg, 10 mg/kg, 25 mg/kg, 50 mg/kg or more {see, e.g., Yang, et al. (2003) New Engl. J. Med. 349:427-434, Herold, et al. (2002) New Engl. J. Med. 346: 1692-1698; Liu, et al. (1999) J. Neurol. Neurosurg. Psych.
67:451-456, Portielji, et al. (20003) Cancer Immunol. Immunother. 52: 133-144). Doses may also be provided to achieve a pre-determined target concentration of anti -human PD-l antibody (or antigen-binding fragment thereof) in the subject’s serum, such as 0.1, 0.3, I, 3, 10, 30, 100, 300 pg/mL or more. In other embodiments, anti-PD-1 antibodies (or antigen-binding fragments thereof) are administered subcutaneously or intravenously, on a weekly, biweekly,“every 4 weeks,” monthly, bimonthly, or quarterly basis at 10, 20, 50, 80, 100, 200, 500, 1000 or 2500 mg/subject.
In specific embodiments of the invention, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered as a 200 mg dose once every 21 days. In alternative embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered as a 240 mg dose once every 2 weeks. In other embodiments, the anti -human PD-l antibody (or antigen-binding fragment thereof) is administered as a 400 mg dose once every 6 weeks. In further embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered as a 480 mg dose once every 4 weeks. In still further embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered at a dose of 2 mg/kg of a patient’s body weight once even 3 weeks (up to a maximum dose of 200 mg). In still additional embodiments, the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered at a dose of 3 mg/kg once every 3 weeks.
The vicriviroc, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient(s) will typically be formulated into a dosage form adapted for administration to a subject by a desired route of administration. For example, dosage forms include those adapted for (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral administration, such as sterile solutions, suspensions, and powders for reconstitution. Suitable pharmaceutically acceptable carriers or excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically acceptable carriers or excipients may be chosen for a particular function that they may serve in the composition. In embodiments, vicriviroc, or a pharmaceutically acceptable salt thereof, may be formulated into a dosage form that allows for systemic use, i.e., distribution of vicriviroc, or a pharmaceutically acceptable salt thereof, throughout the body of the subject; examples of such systemic administration include oral administration and intravenous administration. In additional embodiments, vicriviroc, or a pharmaceutically acceptable salt thereof, may be formulated into a dosage form that allows for targeted or isolated use, i.e., administration of vicriviroc, or a pharmaceutically acceptable salt thereof, only to the portion of the subject’s body to be treated; examples of such targetted administration include intratumoral injection.
Vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
In some embodiments, at least one of the therapeutic agents (the anti -PD- 1 antibody, or binding fragment thereof, and vicriviroc, or a pharmaceutically acceptable salt thereof) in the combination therapy is administered using the same dosage regimen (dose, frequency, and duration of treatment) that is typically employed when the agent is used as monotherapy for treating the same condition. In other embodiments, the patient receives a lower total amount of at least one of the therapeutic agents in the combination therapy than when the agent is used as monotherapy, e.g ., smaller doses, less frequent doses, and/or shorter treatment duration.
A combination therapy of the invention may be used prior to or following surgery to remove a tumor and may be used prior to, during, or after radiation treatment.
In some embodiments, a combination therapy of the invention is administered to a patient who has not previously been treated with a biotherapeutic or chemotherapeutic agent, i.e., is treatment-naive. In other embodiments, the combination therapy is administered to a patient who failed to achieve a sustained response after prior therapy with the biotherapeutic or chemotherapeutic agent, i.e., is treatment-experienced.
Thus, the present disclosure relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days or once every six weeks; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
CELL-PROLIFERATION DISORDERS
The combination therapies disclosed herein are potentially useful in treating diseases or disorders including, but not limited to, cell-proliferation disorders. Cell-proliferation disorders include, but are not limited to, cancers, benign papillomatosis, and gestational trophoblastic diseases. The terms“cancer”,“cancerous”, or“malignant” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
A variety of cancers where PD-L1 or PD-L2 are implicated, whether malignant or benign and whether primary or secondary, may be treated or prevented with a method provided by the disclosure. Particularly preferred cancers that may be treated in accordance with the present disclosure include those characterized by elevated expression of one or both of PD-L1 and PD- L2 in tested tissue samples.
The disease or disorder to be treated is a cell-proliferation disorder. In certain embodiments, the cell-proliferation disorder is cancer.
In particular embodiments, the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, metastatic, microsatellite instability-high (MSI- H) cancer, mismatch repair deficient cancer, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary origin ( i.e ., cancers in which a metastasized cancer is found but the original cancer site is not known). In particular embodiments, the cancer is AIDS-related.
In particular embodiments, the cancer is present in an adult patient; in additional embodiments, the cancer is present in a pediatric patient.
In one embodiment, the invention comprises a method of treating unresectable or metastatic melanoma in a human patient. In another embodiment, the invention comprises a
method for adjuvant therapy of melanoma in a human patient comprising administering a combination therapy of the invention to a patient who has previously had one or more melanoma lesions resected. In some embodiments, the method comprises treating resected high-risk stage III melanoma.
In one embodiment, the invention comprises a method of treating metastatic non small cell lung cancer (NSCLC) in a human patient. In some embodiments, the NSCLC is non- squamous. In other embodiments, the NSCLC is squamous. In some embodiments, the patient has a tumor with high PD-L1 expression [(Tumor Proportion Score (TPS) >50%)] and was not previously treated with platinum-containing chemotherapy. In alternative embodiments, the patient has a tumor with PD-L1 expression (TPS >1%) and was previously treated with platinum-containing chemotherapy. In specific embodiments, the patient had disease progression on or after receiving platinum-containing chemotherapy.
In certain embodiments the PD-L1 TPS is determined by an FDA-approved test.
In certain embodiments of the method for treating NSCLC, the patient’s tumor has no EGFR or ALK genomic aberrations.
In certain embodiments of the method for treating NSCLC, the patient’s tumor has an EGFR or ALK genomic aberration and had disease progression on or after receiving treatment for the EGFR or ALK aberration(s) prior to receiving combination therapy of the invention.
In certain embodiments of the method for treating NSCLC, the method further comprises administering pemetrexed and carboplatin to the patient. In some embodiments, the method further comprises administering folic acid and/or vitamin Bi2to the patient. In further embodiments, the method further comprises administering dexamethasone to the patient.
In certain embodiments of the method for treating NSCLC, the method further comprises administering carboplatin-paclitaxel or nab-paclitaxel to the patient.
In one embodiment, the invention comprises a method of treating recurrent or metastatic head and neck squamous cell cancer (HNSCC) in a human patient. In some embodiments, the patient was previously treated with platinum-containing chemotherapy. In certain embodiments, the patient had disease progression on or after platinum-containing chemotherapy.
In one embodiment, the invention comprises a method of treating refractory classical Hodgkin lymphoma (cHL) in a human patient. In certain embodiments, the patient has relapsed after 1, 2, 3 or more lines of therapy for cHL. In specific embodiments, the patient is an adult patient. In alternative embodiments the patient is a pediatric patient.
In one embodiment, the invention comprises a method of treating locally advanced or metastatic urothelial carcinoma in a human patient. In certain embodiments, the patient is not eligible for cisplatin-containing chemotherapy. In further embodiments, the patient has disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. In specific embodiments, the patient’s tumor expresses PD-L1 (CPS > 10).
In one embodiment, the invention comprises a method of treating unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors in a human patient. In specific embodiments, the patient had disease progression following prior anti-cancer treatment.
In one embodiment, the invention comprises a method of treating unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer in a human patient. In specific embodiments, the patient had disease progression following prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
In one embodiment, the invention comprises a method of treating recurrent locally advanced or metastatic gastric cancer or recurrent locally advanced or metastatic
gastroesophageal junction adenocarcinoma in a human patient. In specific embodiments, the patient’s tumor expresses PD-L1 [Combined Positive Score (CPS) >1] In some embodiments, the patient has disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy. In some embodiments, the patient has disease progression on or after two or more prior lines of therapy including HER2/neu-targeted therapy.
In one embodiment, the invention comprises a method of treating non-Hodgkin lymphoma in a human patient. In certain embodiments, the non-Hodgkin lymphoma is primary mediastinal large B-cell lymphoma.
In one embodiment, the invention comprises a method of treating cancer in a human patient, wherein the patient has a cancer selected from the group consisting of:
melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, bladder cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, lymphoma, renal cancer, mesothelioma, ovarian cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, and salivary cancer.
In one embodiment, the invention comprises a method of treating Merkel cell carcinoma (MCC) in a human patient. In certain embodiments, the cancer is recurrent, locally advanced MCC. In certain embodiments, the cancer is metastatic MCC.
In one embodiment, the invention comprises a method of treating hepatocellular carcinoma (HCC) in a human patient.
In one embodiment, the invention comprises a method of treating renal cell carcinoma (RCC) in a human patient. In certain embodiments, the cancer is advanced clear cell RCC.
In one embodiment, the invention comprises a method of treating breast cancer in a human patient in specific embodiments, the breast cancer is triple negative breast cancer. In other specific embodiments, the breast cancer is ER+/HER2- breast cancer.
In one embodiment, the invention comprises a method of treating cancer in a human patient, wherein the cancer is selected from the group consisting of: melanoma, non-small cell lung cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, gastric cancer, cervical cancer, Merkel cell carcinoma, and hepatocellular carcinoma.
In one embodiment, the invention comprises a method of treating cancer in a human patient comprising, wherein the patient has a tumor with a high mutational burden.
In specific embodiments, the cancer is selected from brain and spinal cancers. In particular embodiments, the brain and spinal cancer is selected from the group consisting of anaplastic astrocytomas, glioblastomas, astrocytomas, and estheosioneuroblastomas (also known as olfactory blastomas). In particular embodiments, the brain cancer is selected from the group consisting of astrocytic tumor ( e.g ., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma), oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma), oligoastrocytic tumor (e.g, oligoastrocytoma, and anaplastic
oligoastrocytoma), ependymoma (e.g, myxopapillary ependymoma, and anaplastic
ependymoma); medulloblastoma, primitive neuroectodermal tumor, schwannoma, meningioma, atypical meningioma, anaplastic meningioma, pituitary adenoma, brain stem glioma, cerebellar astrocytoma, cerebral astorcytoma/malignant glioma, visual pathway and hypothalmic glioma, and primary central nervous system lymphoma. In specific instances of these embodiments, the brain cancer is selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, and suprantentorial primordial neuroectodermal tumors (sPNET).
In specific embodiments, the cancer is selected from cancers of the head and neck, including recurrent or metastatic head and neck squamous cell carcinoma (HNSCC),
nasopharyngeal cancers, nasal cavity and paranasal sinus cancers, hypopharyngeal cancers, oral cavity cancers ( e.g ., squamous cell carcinomas, lymphomas, and sarcomas), lip cancers, oropharyngeal cancers, salivary gland tumors, cancers of the larynx (e.g., laryngeal squamous cell carcinomas, rhabdomyosarcomas), and cancers of the eye or ocular cancers. In particular embodiments, the ocular cancer is selected from the group consisting of intraocular melanoma and retinoblastoma.
In specific embodiments, the cancer is selected from leukemia and cancers of the blood. In particular embodiments, the cancer is selected from the group consisting of myeloproliferative neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), post-MPN AML, post- MDS AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphoma, acute lymphoblastic leukemia, Langerans cell histiocytosis, hairy cell leukemia, and plasma cell neoplasms including plasmacytomas and multiple myelomas. Leukemias referenced herein may be acute or chronic.
In specific embodiments, the cancer is selected from skin cancers. In particular embodiments, the skin cancer is selected from the group consisting of melanoma, squamous cell cancers, and basal cell cancers. In specific embodiments, the skin cancer is unresectable or metastatic melanoma.
In specific embodiments, the cancer is selected from cancers of the reproductive system. In particular embodiments, the cancer is selected from the group consisting of breast cancers, cervical cancers, vaginal cancers, ovarian cancers, endometrial cancers, prostate cancers, penile cancers, and testicular cancers. In specific instances of these embodiments, the cancer is a breast cancer selected from the group consisting of ductal carcinomas and phyllodes tumors. In specific instances of these embodiments, the breast cancer may be male breast cancer or female breast cancer. In some instances of these embodiments, the breast cancer is triple- negative breast cancer. In other instances, the breast cancer is ER+/HER2- breast cancer. In specific instances of these embodiments, the cancer is a cervical cancer selected from the group consisting of squamous cell carcinomas and adenocarcinomas. In specific instances of these embodiments, the cancer is an ovarian cancer selected from the group consisting of epithelial cancers.
In specific embodiments, the cancer is selected from cancers of the gastrointestinal system. In particular embodiments, the cancer is selected from the group consisting of esophageal cancers, gastric cancers (also known as stomach cancers),
gastrointestinal carcinoid tumors, pancreatic cancers, gall bladder cancers, colorectal cancers,
and anal cancer. In instances of these embodiments, the cancer is selected from the group consisting of esophageal squamous cell carcinomas, esophageal adenocarcinomas, gastric adenocarcinomas, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gastric lymphomas, gastrointestinal lymphomas, solid pseudopapillary tumors of the pancreas, pancreatoblastoma, islet cell tumors, pancreatic carcinomas including acinar cell carcinomas and ductal adenocarcinomas, gall bladder adenocarcinomas, colorectal adenocarcinomas, microsatellite stable colorectal cancer, advanced microsatellite stable colorectal cancer, metastatic microsatellite stable colorectal cancer and anal squamous cell carcinomas.
In specific embodiments, the cancer is selected from liver and bile duct cancers.
In particular embodiments, the cancer is liver cancer (also known as hepatocellular carcinoma). In particular embodiments, the cancer is bile duct cancer (also known as cholangiocarcinoma); in instances of these embodiments, the bile duct cancer is selected from the group consisting of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma.
In specific embodiments, the cancer is selected from kidney and bladder cancers. In particular embodiments, the cancer is a kidney cancer selected from the group consisting of renal cell cancer, Wilms tumors, and transitional cell cancers. In particular embodiments, the cancer is a bladder cancer selected from the group consisting of urothelial carcinoma (a transitional cell carcinoma), squamous cell carcinomas, and adenocarcinomas.
In specific embodiments, the cancer is selected from bone cancers. In particular embodiments, the bone cancer is selected from the group consisting of osteosarcoma, malignant fibrous histiocytoma of bone, Ewing sarcoma, chordoma (cancer of the bone along the spine).
In specific embodiments, the cancer is selected from lung cancers. In particular embodiments, the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancers, bronchial tumors, and pleuropulmonary blastomas.
In specific embodiments, the cancer is selected from malignant mesothelioma. In particular embodiments, the cancer is selected from the group consisting of epithelial mesothelioma and sarcomatoids.
In specific embodiments, the cancer is selected from sarcomas. In particular embodiments, the sarcoma is selected from the group consisting of central chondrosarcoma, central and periosteal chondroma, fibrosarcoma, clear cell sarcoma of tendon sheaths, and Kaposi's sarcoma.
In specific embodiments, the cancer is selected from lymphomas. In particular embodiments, the cancer is selected from the group consisting of Hodgkin lymphoma ( e.g ., classical Hodgkin refractory lymphoma), non-Hodgkin lymphoma (e.g., diffuse large B-cell
lymphoma, follicular lymphoma, mycosis fungoides, Sezary syndrome, primary central nervous system lymphoma), cutaneous T-cell lymphomas, primary central nervous system lymphomas.
In specific embodiments, the cancer is selected from glandular cancers. In particular embodiments, the cancer is selected from the group consisting of adrenocortical cancer (also known as adrenocortical carcinoma or adrenal cortical carcinoma), pheochromocytomas, paragangliomas, pituitary tumors, thymoma, and thymic carcinomas.
In specific embodiments, the cancer is selected from thyroid cancers. In particular embodiments, the thyroid cancer is selected from the group consisting of medullary thyroid carcinomas, papillary thyroid carcinomas, and follicular thyroid carcinomas.
In specific embodiments, the cancer is selected from germ cell tumors. In particular embodiments, the cancer is selected from the group consisting of malignant extracranial germ cell tumors and malignant extragonadal germ cell tumors. In specific instances of these embodiments, the malignant extragonadal germ cell tumors are selected from the group consisting of nonseminomas and seminomas.
In specific embodiments, the cancer is selected from heart tumors. In particular embodiments, the heart tumor is selected from the group consisting of malignant teratoma, lymphoma, rhabdomyosacroma, angiosarcoma, chondrosarcoma, infantile fibrosarcoma, and synovial sarcoma.
In specific embodiments, the cell-proliferation disorder is selected from benign papillomatosis, benign neoplastic diseases and gestational trophoblastic diseases. In particular embodiments, the gestational trophoblastic disease is selected from the group consisting of hydati diform moles, and gestational trophoblastic neoplasia ( e.g ., invasive moles,
choriocarcinomas, placental-site trophoblastic tumors, and epithelioid trophoblastic tumors).
In embodiments, the cell-proliferation disorder is a cancer that has metastasized, for example, a liver metastases from colorectal cancer.
In embodiments, the cell-proliferation disorder is selected from the group consisting of solid tumors and lymphomas. In particular embodiments, the cell-proliferation disorder is selected from the group consisting of advanced or metastatic solid tumors and lymphomas. In more particular embodiments, the cell-proliferation disorder is selected from the group consisting of malignant melanoma, head and neck squamous cell carcinoma, breast adenocarcinoma, and lymphomas. In aspects of such embodiments, the lymphomas are selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, mediastinal large B-cell lymphoma, splenic marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated
lymphoid tissue (malt), nodal marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, primary effusion lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma (primary cutaneous type), anaplastic large cell lymphoma (systemic type), peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T-cell lymphoma/leukemia, nasal type extranodal NK/T-cell lymphoma, enteropathy-associated T-cell lymphoma, gamma/delta hepatosplenic T- cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, mycosis fungoides, and Hodgkin lymphoma.
In particular embodiments, the cell-proliferation disorder is classified as stage III cancer or stage IV cancer. In instances of these embodiments, the cancer is not surgically resectable.
In any of the methods of the invention described above, the PD-l antibody or antigen binding fragment can be any anti -PD-l antibody or antigen-binding fragment thereof, including any of the antibodies or antigen-binding fragments described in the section herein entitled“Anti -PD-l Antibodies and Antigen-Binding Fragments Thereof.”
METHODS, USES, AND MEDICAMENTS
Products provided as therapeutic combinations may include a composition comprising an anti-human PD-l antibody (or antigen-binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, together in the same pharmaceutical composition, or may include a composition comprising anti -human PD-l antibody (or antigen-binding fragment thereof), and a composition comprising vicriviroc, or a pharmaceutically acceptable salt thereof, in separate form, e.g., in the form of a kit or in any form designed to enable separate administration either concurrently or on separate dosing schedules.
The combination therapy may also comprise one or more additional therapeutic agents. The additional therapeutic agent may be, e.g. , a chemotherapeutic, a biotherapeutic agent (including but not limited to antibodies or antigen-binding fragments thereof that specifically bind to an antigen selected from the group consisting of: PD-L1, PD-L2, CTLA4, LAG3, BTLA, TIM3, HVEM, GITR, CD27, TIGIT, ILT2, ILT3, ILT4, ILT5, SIRPa, NKG2A, NKG2C, NKG2E, TSLP, IL10, VISTA, VEGF, EGFR, Her2/neu, VEGF receptors, other growth factor receptors, CD20, CD28, CD40, CD-40L, CD70, OX-40, 4-1BB, and ICOS). The one or more additional active agents may be co-administered either with the anti-human PD-l antibody (or antigen-binding fragment thereof) or with vicriviroc, or a pharmaceutically acceptable salt thereof. The additional active agent(s) may be administered in a single dosage form with one or more co-administered agent selected from the anti -human PD-l antibody (or antigen-binding fragment thereof) and vicriviroc, or a pharmaceutically acceptable salt thereof, or the additional
active agent(s) may be administered in separate dosage form(s) from the dosage forms containing the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof.
The therapeutic combination disclosed herein may be used in combination with one or more other active agents, including but not limited to, other anti-cancer agents that are used in the prevention, treatment, control, amelioration, or reduction of risk of a particular disease or condition ( e.g ., cell-proliferation disorders). In one embodiment, a compound disclosed herein is combined with one or more other anti -cancer agents for use in the prevention, treatment, control amelioration, or reduction of risk of a particular disease or condition for which the compounds disclosed herein are useful. Such other active agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present disclosure.
The additional active agent(s) may be one or more agents selected from the group consisting of STING agonists, poly ADP ribose polymerase (PARP) inhibitors, mitogen- activated protein kinase (MEK) inhibitors, cyclin-dependent kinase (CDK) inhibitors, indoleamine 2,3 -di oxygenase (IDO) inhibitors, tryptophan 2,3 -di oxygenase (TDO) selective inhibitors, anti-viral compounds, antigens, adjuvants, anti-cancer agents, CTLA-4, LAG-3 and PD-l pathway antagonists, lipids, liposomes, peptides, cytotoxic agents, chemotherapeutic agents, immunomodulatory cell lines, checkpoint inhibitors, vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, and immunomodulatory agents including but not limited to anti-cancer vaccines. It will be understood the descriptions of the above additional active agents may be overlapping. It will also be understood that the treatment combinations are subject to optimization, and it is understood that the best combination to use of the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or the CXCR2 antagonist, and one or more additional active agents will be determined based on the individual patient needs.
When the therapeutic combination disclosed herein is used contemporaneously with one or more other active agents, the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof, may be administered either simultaneously with, or before or after, one or more other active agent(s). Either of the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof, may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).
The weight ratio of the anti-human PD-l antibody (or antigen-binding fragment thereof) to vicriviroc, or a pharmaceutically acceptable salt thereof, may be varied and will depend upon the therapeutically effective dose of each agent. Generally, a therapeutically effective dose of each will be used. Combinations including at least one anti -human PD-l antibody (or antigen-binding fragment thereof), vicriviroc, or a pharmaceutically acceptable salt thereof, and other active agents will generally include a therapeutically effective dose of each active agent. In such combinations, the anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof, disclosed herein and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent with, or subsequent to the
administration of other agent(s).
In one embodiment, this disclosure provides an anti-human PD-l antibody (or antigen-binding fragment thereof) and/or vicriviroc, or a pharmaceutically acceptable salt thereof, and at least one other active agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a cell- proliferation disorder, such as cancer.
In one embodiment, the disclosure provides a kit comprising two or more separate pharmaceutical compositions, one of which contains a anti-human PD-l antibody (or antigen binding fragment thereof) and another of which contains vicriviroc, or a pharmaceutically acceptable salt thereof. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. A kit of this disclosure may be used for administration of different dosage forms, for example, oral and parenteral, for administration of the separate compositions at different dosage intervals, or for titration of the separate compositions against one another. To assist with compliance, a kit of the disclosure typically comprises directions for administration.
The disclosure also provides the use of vicriviroc, or a pharmaceutically acceptable salt thereof, for treating a cell-proliferation disorder, where the patient has previously ( e.g ., within 24 hours) been treated with an anti-human PD-l antibody (or antigen-binding fragment thereof). The disclosure also provides the use of an anti-human PD-l antibody (or antigen-binding fragment thereof) for treating a cell-proliferation disorder, where the patient has previously (e.g., within 24 hours) been treated with vicriviroc, or a pharmaceutically acceptable salt thereof.
Anti-viral compounds that may be used in combination with the therapeutic combinations disclosed herein include hepatitis B virus (HBV) inhibitors, hepatitis C virus
(HCV) protease inhibitors, HCV polymerase inhibitors, HCV NS4A inhibitors, HCV NS5A inhibitors, HCV NS5b inhibitors, and human immunodeficiency virus (HIV) inhibitors.
Antigens and adjuvants that may be used in combination with the therapeutic combinations disclosed herein include B7 costimulatory molecule, interleukin-2, interferon-g, GM-CSF, CTLA-4 antagonists, OX-40/0X-40 ligand, CD40/CD40 ligand, sargramostim, levamisol, vaccinia virus, Bacille Calmette-Guerin (BCG), liposomes, alum, Freund's complete or incomplete adjuvant, detoxified endotoxins, mineral oils, surface active substances such as lipolecithin, pluronic polyols, polyanions, peptides, and oil or hydrocarbon emulsions.
Adjuvants, such as aluminum hydroxide or aluminum phosphate, can be added to increase the ability of the vaccine to trigger, enhance, or prolong an immune response. Additional materials, such as cytokines, chemokines, and bacterial nucleic acid sequences, like CpG, a toll-like receptor (TLR) 9 agonist as well as additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8, TLR9, including lipoprotein, lipopolysaccharide (LPS), monophosphoryllipid A, lipoteichoic acid, imiquimod, resiquimod, and in addition retinoic acid-inducible gene I (RIG-I) agonists such as poly I:C, used separately or in combination are also potential adjuvants.
Examples of cytotoxic agents that may be used in combination with the therapeutic combinations disclosed herein include, but are not limited to, arsenic trioxide (sold under the tradename TRISENOX®), asparaginase (also known as L-asparaginase, and Erwinia L- asparaginase, sold under the tradenames ELSPAR® and KIDROLASE®).
Chemotherapeutic agents that may be used in combination with the therapeutic combinations disclosed herein include abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4- methoxyphenyl)benzene sulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L- valyl-L-prolyl- l-Lproline-t-butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3',4'-didehydro-4'deoxy-8'-norvin-caleukoblastine, dinaciclib, docetaxol, doxetaxel,
cyclophosphamide, carboplatin, carmustine, cisplatin, cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine dolastatin, doxorubicin (adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyurea andtaxanes, ifosfamide, liarozole, lonidamine, lomustine, MDV3100, mechlorethamine (nitrogen mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef, streptozocin, mitomycin, methotrexate, taxanes, nilutamide, olaparib, onapristone, paclitaxel, prednimustine, procarbazine, RPR109881, selumetinib, stramustine phosphate, tamoxifen, tasonermin, taxol, tretinoin, vinblastine, vincristine, vindesine sulfate, and vinflunine, and pharmaceutically acceptable salts thereof.
Examples of vascular endothelial growth factor (VEGF) receptor inhibitors include, but are not limited to, bevacizumab (sold under the trademark AVASTIN by
Genentech/Roche), axitinib (described in PCT International Patent Publication No.
W001/002369), Brivanib Alaninate ((S)-((R)-l-(4-(4-Fluoro-2-methyl-lH-indol-5-yloxy)-5- methylpyrrolo[2,l-f][l,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS- 582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-lH-indol-6-yl)-2-[(4-pyridinylmethyl)amino]- 3-pyridinecarboxamide. and described in PCT International Patent Application Publication No. W002/068470), pasireotide (also known as SO 230, and described in PCT International Patent Publication No. W002/010192), and sorafenib.
Examples of topoisomerase II inhibitors, include but are not limited to, etoposide, and teniposide.
Examples of alkylating agents, include but are not limited to, 5-azacytidine, decitabine, temozolomide, dactinomycin (also known as actinomycin-D, melphalan, altretamine, carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil,
cyclophosphamide, dacarbazine, altretamine, ifosfamide, procarbazine, mechlorethamine, streptozocin , thiotepa, and pharmaceutically acceptable salts thereof.
Examples of anti-tumor antibiotics include, but are not limited to, doxorubicin, bleomycin , daunorubicin daunorubicin liposomal (daunorubicin citrate liposome),
mitoxantrone, epirubicin , idarubicin, and mitomycin C.
Examples of anti-metabolites include, but are not limited to, claribine , 5- fluorouracil, 6-thioguanine, pemetrexed (sold under the tradename ALIMTA®), cytarabine (also known as arabinosylcytosine (Ara-C)), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DEPOCYT™), decitabine (sold under the tradename DACOGEN®), hydroxyurea and fludarabine, floxuridine, cladribine (also known as 2-chlorodeoxyadenosine (2- CdA), methotrexate (also known as amethopterin, methotrexate sodium (MTX)), and pentostatin.
Examples of retinoids include, but are not limited to, alitretinoin, tretinoin, isotretinoin, and bexarotene.
ADDITIONAL EMBODIMENTS
The present disclosure further relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l
antibody (or antigen-binding fragment thereof) is administered once every 21 days; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
The present disclosure further relates to methods of treating a cell-proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the anti-human PD-l antibody (or antigen-binding fragment thereof) is administered once every 21 days; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered once daily.
Additionally, the present disclosure relates to methods of treating a cell- proliferation disorder, said method comprising administering to a subject in need thereof a combination therapy that comprises (a) an anti-human PD-l antibody (or antigen-binding fragment thereof); and (b) vicriviroc, or a pharmaceutically acceptable salt thereof; wherein the cell-proliferation disorder is cancer. In specific embodiments, the cancer occurs as one or more solid tumors or lymphomas. In further specific embodiments, the cancer is selected from the group consisting of advanced or metastatic solid tumors and lymphomas. In still further specific embodiments, the cancer is selected from the group consisting of malignant melanoma, head and neck squamous cell carcinoma, MSI-H cancer, MMR deficient cancer,, non-small cell lung cancer, urothelial carcinoma, gastric or garoesophageal junction adenocarcinoma, breast adenocarcinoma, and lymphomas. In additional embodiments, the lymphoma is selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, mediastinal large B-cell lymphoma, splenic marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (malt), nodal marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, primary effusion lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma (primary cutaneous type), anaplastic large cell lymphoma (systemic type), peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T-cell lymphoma/leukemia, nasal type extranodal NK/T-cell lymphoma, enteropathy-associated T-cell lymphoma, gamma/delta hepatosplenic T- cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, mycosis fungoides, and Hodgkin lymphoma. In particular embodiments, the cell-proliferation disorder is a cancer that has metastasized, for example, a liver metastases from colorectal cancer. In additional embodiments, the cell-proliferation disorder is a cancer is classified as stage III cancer or stage IV cancer. In instances of these embodiments, the cancer is not surgically resectable.
In embodiments of the methods disclosed herein, the anti-human PD-l antibody is an anti -PD-l monoclonal antibody. In particular aspects of these embodiments, the anti-human
PD-l antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, and AMP-224. In specific aspects of these embodiments, the anti-human PD-l antibody is selected from nivolumab and pembrolizumab. In a more specific aspect, the anti-human PD-l antibody is nivolumab. In a further specific aspect, the anti-human PD-l antibody is
pembrolizumab.
In embodiments of the methods disclosed herein, the anti-human PD-l antibody (or antigen binding fragment thereof) is administered by intravenous infusion or subcutaneous injection, and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered orally, by intravenous infusion, by intratumoral injection, or by subcutaneous injection.
In embodiments of the methods disclosed herein, the anti-human PD-l antibody (or antigen binding fragment thereof) is administered by intravenous infusion or subcutaneous injection, and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered orally.
In embodiments of the methods disclosed herein, the anti-human PD-l antibody (or antigen binding fragment thereof) is administered prior to administration of thevicriviroc, or a pharmaceutically acceptable salt thereof. In alternative embodiments of the methods disclosed herein, the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered prior to administration of the anti-human PD-l antibody (or antigen binding fragment thereof).
In embodiments of the methods disclosed herein, the anti-human PD-l antibody (or antigen binding fragment thereof) is administered at a dose of 200 mg; and the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered at a dose of from 150 mg to 250 mg. In aspects of such embodiments, the vicriviroc, or a pharmaceutically acceptable salt thereof, is administered at a dose of 150 mg or 250 mg. Further aspects of the invention, comprise vicriviroc maleate.
Additional embodiments of the disclosure include the pharmaceutical compositions, combinations, uses and methods set forth in above, wherein it is to be understood that each embodiment may be combined with one or more other embodiments, to the extent that such a combination is consistent with the description of the embodiments. It is further to be understood that the embodiments provided above are understood to include all embodiments, including such embodiments as result from combinations of embodiments.
GENERAL METHODS
Standard methods in molecular biology are described Sambrook, Fritsch and Maniatis (1982 & 1989 2nd Edition, 2001 3rd Edition) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Sambrook and Russell (2001)
Molecular Cloning, 3rd ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Wu (1993) Recombinant DN A, Vol. 217, Academic Press, San Diego, CA). Standard methods also appear in Ausbel, et al. (2001) Current Protocols in Molecular Biology, Vo/s.1 -4, John Wiley and Sons, Inc. New York, NY, which describes cloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning in mammalian cells and yeast (Vol. 2), glycoconjugates and protein expression (Vol. 3), and bioinformatics (Vol. 4).
Methods for protein purification including immunoprecipitation, chromatography, electrophoresis, centrifugation, and crystallization are described (Coligan, et al. (2000) Current Protocols in Protein Science, Vol. 1, John Wiley and Sons, Inc., New York). Chemical analysis, chemical modification, post-translational modification, production of fusion proteins, glycosylation of proteins are described (see, e.g, Coligan, et al. (2000) Current Protocols in Protein Science, Vol. 2, John Wiley and Sons, Inc., New York; Ausubel, et al. (2001) Current Protocols in Molecular Biology, Vol. 3, John Wiley and Sons, Inc., NY, NY, pp. 16.0.5- 16.22.17; Sigma-Aldrich, Co. (2001 ) Products for Life Science Research, St. Louis, MO; pp. 45- 89; Amersham Pharmacia Biotech (2001) BioDirectory, Piscataway, N.J., pp. 384-391).
Production, purification, and fragmentation of polyclonal and monoclonal antibodies are described (Coligan, et al. (2001) Current Protocols in Immunology, Vol. 1, John Wiley and Sons, Inc., New York; Harlow and Lane (1999) Using Antibodies, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Harlow and Lane, supra). Standard techniques for
characterizing ligand/receptor interactions are available (see, e.g, Coligan, et al. (2001) Current Protocols in Immunology, Vol. 4, John Wiley, Inc., New York).
Monoclonal, polyclonal, and humanized antibodies can be prepared (see, e.g, Sheperd and Dean (eds.) (2000) Monoclonal Antibodies, Oxford Univ. Press, New York, NY; Kontermann and Dubel (eds.) (2001) Antibody Engineering, Springer- Verlag, New York;
Harlow and Lane (1988) Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 139-243; Carpenter, et al. (2000) J. Immunol. 165:6205; He, et al. (1998) J. Immunol. 160: 1029; Tang et al. (1999) J. Biol. Chem. 274:27371-27378; Baca et al. (1991) J. Biol. Chem. 272: 10678-10684; Chothia et al. (1989 ) Nature 342:877-883; Foote and Winter (1992) J. Mol. Biol. 224:487-499; U.S. Pat. No. 6,329,511).
An alternative to humanization is to use human antibody libraries displayed on phage or human antibody libraries in transgenic mice (Vaughan et al. (1996) Nature Biotechnol. 14:309-314; Barbas (1995) Nature Medicine 1 :837-839; Mendez et al. (1997) Nature Genetics 15: 146-156; Hoogenboom and Chames (2000) Immunol. Today 21 :371-377; Barbas et al. (2001)
Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, New York; Kay et al. (1996) Phage Display of Peptides and Proteins: A Laboratory Manual , Academic Press, San Diego, CA; de Bruin et al. (1999) Nature Biotechnol. 17:397- 399).
Purification of antigen is not necessary for the generation of antibodies. Animals can be immunized with cells bearing the antigen of interest. Splenocytes can then be isolated from the immunized animals, and the splenocytes can fused with a myeloma cell line to produce a hybridoma (see, e.g, Meyaard et al. (1997) Immunity 7:283-290; Wright et al. (2000) Immunity 13:233-242; Preston et al, supra, Kaithamana et al. (1999) J. Immunol. 163:5157-5164).
Methods for flow cytometry, including fluorescence activated cell sorting
(FACS), are available (see, e.g, Owens, et al. (1994 ) Flow Cytometry Principles for Clinical Laboratory Practice, John Wiley and Sons, Hoboken, NJ; Givan (2001 ) Flow Cytometry, 2nd ed.; Wiley-Liss, Hoboken, NJ; Shapiro (2003) Practical Flow Cytometry, John Wiley and Sons, Hoboken, NJ). Fluorescent reagents suitable for modifying nucleic acids, including nucleic acid primers and probes, polypeptides, and antibodies, for use, e.g. , as diagnostic reagents, are available (Molecular Probesy (2003) Catalogue, Molecular Probes, Inc., Eugene, OR; Sigma- Aldrich (2003) Catalogue, St. Louis, MO).
Standard methods of histology of the immune system are described (see, e.g, Muller-Harmelink (ed.) (1986) Human Thymus: Histopathology and Pathology, Springer Verlag, New York, NY; Hiatt, et al. (2000) Color Atlas of Histology, Lippincott, Williams, and Wilkins, Phila, PA; Louis, et al. (2002) Basic Histology: Text and Atlas, McGraw-Hill, New York, NY).
Software packages and databases for determining, e.g, antigenic fragments, leader sequences, protein folding, functional domains, glycosylation sites, and sequence alignments, are available (see, e.g, GenBank, Vector NTI® Suite (Informax, Inc., Bethesda, MD); GCG Wisconsin Package (Accelrys, Inc., San Diego, CA); DeCypher® (TimeLogic Corp., Crystal Bay, Nevada); Menne, et al. (2000) Bioinformatics 16: 741-742; Menne, et al. (2000) Bioinformatics Applications Note 16:741-742; Wren, et al. (2002) Comput. Methods Programs Biomed. 68:177-181; von Heijne (1983 ) Eur. J. Biochem. 133: 17-21; von Heijne ( 1986) Nucleic Acids Res. 14:4683-4690).
EXAMPLES
EXAMPLE 1
EXPRESSION OF CCR5 AND LIGANDS
CCR5 is expressed by T cells, including tissue-infiltrating lymphocytes and myeloid cells, including macrophages and monocytes. See, Weitzenfeld P, Ben-Baruch A.,“The
Chemokine System, and its CCR5 and CXCR4 receptors, as Potential Targets for Personalized Therapy in Cancer,” Cancer Lett. 2014 Sep 28;352(l):36-53. CCR5 is known to be an important co-receptor for macrophage-tropic viruses, including HIV, to enter host cells. Per the Genotype- Tissue Expression database, the organs with the most expression are spleen (4.1 reads per kilobase million [RPKM]), lung (2 RPKM), and small intestine (2 RPKM), with all other expression <1 RPKM.
The pattern and relative levels of CCR5 messenger ribonucleic acid (mRNA) expression in human cancers were examined using microarray transcriptomic data analysis with an Affymetrix custom Merck array. Cancer indications with >100 samples each were profiled in the Merck Moffitt tumor molecular database (total sample size is 16,120). The Merck Moffitt tumor molecular database analysis shows that CCR5 expression is observed to be more prevalent in mCRC compared with primary CRC (N=300 subjects). As shown in Figure 1, the Moffitt tumor molecular database analysis also shows that CCR5 is detected broadly across multiple human tumor subsets, including triple negative breast cancer, clear cell kidney cancer (renal cell carcinoma), lung adenocarcinoma, cervical cancer, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, squamous cell lung cancer, melanoma, colorectal microsatellite instability (MSI) high, luminal B breast cancer, head and neck cancer, pancreatic adenocarcinoma, luminal A breast cancer, liver cancer, gastric cancer, serous cell ovarian cancer, esophageal adenocarcinoma, uterine/endometrial-MSI high cancer, sarcoma, urothelial bladder cancer, small cell lung cancer, glioblastoma, and prostate cancer.
The following abbreviations are used in Figure 1 : HER2+ = human epidermal growth factor receptor 2 positive; mRNA = messenger ribonucleic acid. The expression values are quantile normalized, log 10 Affymetrix intensity; these values are shown on the x-axis.
Values above 0.7 are associated with expression above the limit of detection. Vertical bars in each rectangle represent the median value; vertical bars at the end of each dashed line represent the bottom and top quartiles of the distribution for each indication. The small crosses represent individual outlier data points.
EXAMPLE 2
BINDING OF VICRIVIROC TO HUMAN CCR5
Vicriviroc binds to CCR5 with high affinity. See, Strizki JM, Tremblay C, Xu S,
Wojcik L, Wagner N, Gonsiorek W.,“Discovery and Characterization of Vicriviroc (SCH
417690), a CCR5 Antagonist with Potent Activity Against Human Immunodeficiency Virus Typel” Antimicrob Agents Chemother. 2005 Dec;49(l2):49l 1-9. In competitive binding assays using [3-H]-SCH-C:
a small molecule selective CCR5 antagonist that binds CCR5 with a dissociation constant (Kd) = 1.25 ± 0.55 nM, vicriviroc had an inhibitory constant (Ki) of 0.8 nM. The [3-HJ-SCH-C competitive binding studies were performed over a 36-hour time course to approach equilibrium, using membranes from Chinese hamster ovary (CHO) cells engineered to express human CCR5. In cross-competition experiments, SCH-C had a Ki of 2.6 nM. The half-life of the vicriviroc drug-receptor complex was 13 hours at 25°C.
In nonequilibrium studies with [3-H]-vicriviroc (See, Strizki, JM, et al., cited above), binding to CCR5 membranes was saturable and reversible, with a calculated Kd of 0.159 ± 0.009 nM. In further nonequilibrium studies on CCR5 membranes using unlabeled compounds and an orthosteric radioligand with known binding kinetics, the affinity constant (Kd) for vicriviroc was 0.4 ± 0.02 nM. In this same assay the Kd for SCH-C was 0.91 ± 0.10 nM. The Kd values are comparable to the competitive binding Ki values.
EXAMPLE 3
ANTAGONISM OF CCR5 RECEPTOR SIGNALING
Vicriviroc antagonized receptor signaling in a number of in vitro assays.
Vicriviroc inhibited binding of the natural ligand CCL5 to CCR5. Vicriviroc also prevented ligand-induced CCR5 signaling, as shown by inhibition of cell migration, calcium flux, and G-protein binding for all 3 natural ligands, CCL5, CCL3, and CCL4:
Abbreviations: CCL = cysteine-cysteine motif chemokine ligand; IC50 = half-maximal inhibitory concentration; Kd = dissociation constant; Ki = inhibitory constant; nM = nanomolar. a Membranes from CHO cells expressing human CCR5 were incubated with vicriviroc in the presence of 50 pM [l25-I]-labeled CCL5 for 1 hour. Reaction mixtures were filtered and washed, and bound CCL5 determined by liquid scintillation counting. Ki values were calculated from experimental IC50 and Kd values.
b BaF3 cells stably transfected with CCR5 were pretreated for 1 hour with different
concentrations of vicriviroc. Chemotaxis buffer containing CCL5, CCL3, or CCL4 was placed in the bottom well of a ChemoTx plate and filter unit placed over. The vicriviroc-pretreated Ba/F3- CCR5 cells were placed on the filter and plates incubated for 2 hours. Cells remaining on the filter were transferred to a separate plate and quantified using the Cell Titer Glow luminescent cell viability kit (Promega).
c B550 cells were preloaded with Fura 2AM (Sigma) for 1 hour prior to re-suspending in Hanks Balanced Salt Solution (HBSS) with 1% fetal calf serum, and transferring to a cuvette with flux buffer (HBSS, 10 mM HEPES, 1.6 mM calcium chloride). Vicriviroc was added at 0.01, 0.1, or 1.0 mM. Intracellular calcium flux was monitored by the ratio of fluorescence at 340 nm to 380 nm in a LS-50B Luminescence fluorimeter (Perkin Elmer) after the addition of 10 nM
CCL5.
d CCR5 signaling was assessed by G-protein binding using a scintillation proximity assay (SPA) and membranes from Chinese hamster ovary cells expressing human CCR5. Membrane-coated SPA beads were incubated with 10 pM guanosine-5 '-diphosphate in the presence or absence of ligand and/or vicriviroc for 1 hour. Guanosine-5 '-[g-35 -S] -triphosphate ([35-S]-GTPyS) (0.1 nM) was added for 1 hour additional incubation. Reaction mixtures were filtered and
membranes washed, and membrane-bound [35-S]-GTPyS determined by liquid scintillation counting. Signaling correlates with bound [35-S]-GTPyS.
EXAMPLE 4
IN VITRO ACTIVITY OF VICRIVIROC ON TUMOR CELL PROLIFERATION
Vicriviroc was tested for its ability to inhibit tumor cell proliferation using the MV-4-11 cell line. MV-4-11 cells are an acute myeloma cell line established from the blast cells of a lO-year-old male with biphenotypic B-myelomonocytic leukemia, and were confirmed to have CCR5 expression using flow cytometry.
MV-4-11 cells were plated into 96-well Coming™ BioCoat™ Poly-D-Lysine microplates into which media containing either vicriviroc at 0.01, 0.1, 1, or 10 mM, CCL5 at 0.1, 1, 10, or 100 ng/mL, or no treatment had been added. Plates were incubated in the IncuCyte Zoom™ system (Essen Bioscience) at 37°C for 70 to 72 hours, with a 2-hour phase interval and phase channel selection to collect % confluency data. As shown in Figure 2, mean % confluency ± standard deviation from plating (time 0) to 70 hours during exposure to vicriviroc (Panel A) or to CCL5 (Panel B). A 2-way ANOVA main column effect with Bonferroni’s multiple comparison test was used to determine whether treatment with vicriviroc or CCL5 was significantly different from the untreated control, with **** indicating / 0.0001 Exposure to either vicriviroc or to CCL5 resulted in significant changes in proliferation, confirming the responsiveness of the cell line to this receptor-signaling pathway.
EXAMPLE 5
IN VITRO ACTIVITY OF VICRIVIROC IN COMBINATION WITH PEMBROLIZUMAB ON RHESUS MONKEY PERIPHERAL BLOOD MONONUCLEAR CELLS
To determine whether vicriviroc treatment might be able to enhance the antitumor activity of PD-l blockade, antigen-specific activity of vicriviroc was evaluated in combination with pembrolizumab for the ability to increase expression of IFN-g in peripheral blood mononuclear cells (PBMC) from rhesus monkeys previously vaccinated with
cytomegalovirus (CMV). Rhesus monkey PBMC were incubated with 10 nM vicriviroc alone, 1 or 10 pg/mL pembrolizumab alone, or in combination with 10 nM vicriviroc in the presence of whole inactivated CMV. Cytokine secretion was detected using an immunoassay.
Peripheral blood mononuclear cells from 4 rhesus monkeys previously vaccinated with CMV were stimulated ex vivo with inactivated CMV along with a cocktail of 10 or 1 pg/mL pembrolizumab and 10 nM vicriviroc or control for 72 hours. Interferon gamma (IFN-g) secretion in the supernatant was analyzed using an immunoassay. Results are shown as mean
values of IFN-g in Figure 3. Error bars indicate standard error of the mean. An increase in mean IFN-g secretion was observed with vicriviroc in combination with pembrolizumab (cross-hatched bars) versus pembrolizumab alone (open bars) or vicriviroc alone (stippled bar). Significance was calculated using the paired t test in GraphPad Prism.
Interferon gamma (IFN-g) secretion increased with combination treatment compared with treatment with pembrolizumab alone. As shown in Figure 3, vicriviroc caused a dose-dependent and comparable increase in CCR5 levels on human and rhesus monkey PBMC.
Claims
1. A method of treating a cell proliferation disorder, comprising administering:
(a) vicriviroc, or a pharmaceutically acceptable salt thereof; and
(b) an anti-human PD-l antibody or antigen binding fragment thereof to a human patient in need thereof.
2. The method of claim 1, wherein the cell-proliferation disorder is cancer.
3. The method of claim 2, wherein the cancer is microsatellite stable colorectal cancer, prostate cancer, pancreatic cancer, melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, non-Hodgkin lymphoma, renal cancer, Hodgkin lymphoma,
mesothelioma, metastatic, microsatellite instability-high cancer, mismatch repair deficient cancer, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, or salivary cancer.
4. The method of claim 2, wherein the cancer is cancer melanoma, NSCLC, head and neck squamous cell cancer (HNSCC), Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability -high cancer, gastric cancer, Merkel cell carcinoma, hepatocellular carcinoma or cervical cancer.
5. The method of claim 2, wherein the cancer is microsatellite stable colorectal cancer.
6. The method of claim 5, comprising vicriviroc maleate and an anti-human PD-l antibody or antigen binding fragment thereof.
7. The method of claim 1, wherein the human patient is administered:
(a) 200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate; or
(b) 2 mg/kg of an anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate or a pharmaceutically acceptable salt thereof,
wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily.
8. The method of claim 1, wherein the human patient is administered 240 mg of the anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every two weeks and the vicriviroc maleate is administered once daily.
9. The method of claim 1, wherein the human patient is administered 400 mg of the anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every six weeks and the vicriviroc maleate is administered once daily.
10. The method of claim 1, wherein the human patient is administered 480 mg of the anti-human PD-l antibody or antigen binding fragment thereof and from 150 to 250 mg of vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every four weeks and the vicriviroc maleate is administered once daily.
11. The method of claim 7 wherein the human patient is administered:
200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and 150 mg vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily.
12. The method of claim 7 wherein wherein the human patient is administered: 200 mg of the anti-human PD-l antibody or antigen binding fragment thereof and 250 mg vicriviroc maleate; wherein the anti-human PD-l antibody or antigen binding fragment thereof is administered once every three weeks and the vicriviroc maleate is administered once daily.
13. A kit compri sing :
(a) vicriviroc maleate; and
(b) an anti-human PD-l antibody or antigen binding fragment thereof.
14. The kit of claim 11, further comprising instructions for administering vicriviroc maleate and the anti-human PD-l antibody or antigen binding fragment thereof to a human patient.
15. Use of a therapeutic combination, comprising:
(a) vicriviroc, or a pharmaceutically acceptable salt therof; and
(b) an anti-human PD-l antibody or antigen binding fragment thereof for treating a cell proliferation disorder in a human patient.
16. The use of claim 13 comprising vicriviroc maleate and an anti-human PD- 1 antibody or antigen binding fragment thereof.
17. The method, kit, or use of any of claims 1-16, wherein the anti-human PD- 1 antibody or antigen binding fragment thereof comprises three light chain CDRs of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3 and three heavy chain CDRs of SEQ ID NO:6, SEQ ID NO: 7 and SEQ ID NO:8.
18. The method, kit, or use of any of claims 1-16, wherein the anti-human PD- 1 antibody or antigen binding fragment thereof comprises a VL region which comprises the amino acid sequence set forth in SEQ ID NO:4, and a VH region which comprises the amino acid sequence set forth in SEQ ID NO:9.
19. The method, kit, or use of any of claims 1-16, wherein the anti-human PD- 1 antibody or antigen binding fragment thereof comprises a light chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO: 10.
20. The method, kit, or use of any of claims 1-16, wherein the anti-human PD- 1 antibody or antigen binding fragment thereof is pembrolizumab.
21. The method, kit, or use of any of claims 1-16, wherein the anti-human PD- 1 antibody or antigen binding fragment thereof is nivolumab.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862716561P | 2018-08-09 | 2018-08-09 | |
US62/716,561 | 2018-08-09 | ||
US201962859950P | 2019-06-11 | 2019-06-11 | |
US62/859,950 | 2019-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020033283A1 true WO2020033283A1 (en) | 2020-02-13 |
Family
ID=69414298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/045041 WO2020033283A1 (en) | 2018-08-09 | 2019-08-05 | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020033283A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4073099A4 (en) * | 2019-12-15 | 2024-01-03 | Baruch S. Blumberg Institute | Methods, kits and compositions for reducing cardiotoxicity associated with cancer therapies |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009134637A1 (en) * | 2008-04-28 | 2009-11-05 | Schering Corporation | Piperazine-based ccr5 antagonist tablet dosage form |
US20160022814A1 (en) * | 2014-07-18 | 2016-01-28 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
WO2017210637A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
-
2019
- 2019-08-05 WO PCT/US2019/045041 patent/WO2020033283A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009134637A1 (en) * | 2008-04-28 | 2009-11-05 | Schering Corporation | Piperazine-based ccr5 antagonist tablet dosage form |
US20160022814A1 (en) * | 2014-07-18 | 2016-01-28 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
WO2017210637A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
Non-Patent Citations (2)
Title |
---|
DOSSET, M ET AL.: "PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer", ONCOIMMUNOLOGY, vol. 7, no. 6, 15 March 2018 (2018-03-15), pages 1 - 14, XP055684370 * |
SULEIMAN, J ET AL.: "Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial", THE JOURNAL OF INFECTIOUS DISEASE, vol. 201, no. 4, 15 February 2010 (2010-02-15), pages 590 - 599, XP055684356 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4073099A4 (en) * | 2019-12-15 | 2024-01-03 | Baruch S. Blumberg Institute | Methods, kits and compositions for reducing cardiotoxicity associated with cancer therapies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11312772B2 (en) | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | |
US20240092902A1 (en) | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody | |
US20190328762A1 (en) | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment | |
KR102662228B1 (en) | Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer | |
RU2705795C2 (en) | Treating cancer with combination of pd-1 antagonist and dinaciclib | |
TWI663983B (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer | |
KR20170122810A (en) | A combination of PD-1 antagonist and eribulin for treating cancer | |
KR20190082782A (en) | A combination of PD-1 antagonist and eribulin for the treatment of urinary tract carcinoma | |
US20230365678A1 (en) | Dosing regimens of anti-ilt4 antibody or its combination with anti-pd-1 antibody for treating cancer | |
KR20220123017A (en) | A method of treating cancer using a combination of a PD-1 antagonist, an ILT4 antagonist and a chemotherapeutic agent | |
WO2020033283A1 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc | |
US11052065B2 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | |
US20240010729A1 (en) | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer | |
KR20240038769A (en) | How to Treat Acute Myeloid Leukemia Using Anti-ILT3 Antibodies | |
CN116322767A (en) | Improving antibody tolerance in connection with intravenous administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19846884 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19846884 Country of ref document: EP Kind code of ref document: A1 |